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ABSTRACT
Heminger, Katherine Ann. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2007. Loss of HdmX Leads to Alterations in Gene Expression and Inhibition
of Cell Growth in Tumor Cells with Wild-type p53.

Mutations in the p53 tumor suppressor gene are among the most prevalent
molecular abnormalities in human cancer. While half of all human tumors possess p53
mutations, inactivation of wild-type p53 can also occur through a variety of mechanisms
that do not involve p53 gene mutation or deletion. This dissertation focuses on human
tumor cell lines harboring wild-type p53 protein and elevated levels of HdmX and/or
Hdm2, two critical negative regulators of p53 function. My hypothesis is that loss of
HdmX in tumor cells with wild-type p53 and over-expressed HdmX, will activate p53
and induce p53 target genes leading to growth inhibition. To test this hypothesis, RNA
interference (RNAi) was utilized to knockdown HdmX protein from HdmX overexpressing breast, colon, and bone tumor cell lines. Alterations in gene expression and
effects on cell proliferation following the removal of HdmX were examined. Two RNAi
approaches were assessed in this study; transient small interfering RNA (siRNA)
transfection and lentivirus-delivered short-hairpin RNA (shRNA) vectors. Multiple
siRNA transfections were selected as the method of choice over the shRNA vectors due
to the induction of off-target genes in cells expressing the shRNA vectors. Affymetrix
GeneChips and subsequent quantitative real time-PCR validations were used to uncover a
subset of p53 target genes encoding proteins associated with cell cycle arrest and growth
inhibition that were induced upon HdmX knockdown. In contrast, only one p53
dependent pro-apoptotic gene (i.e. Fas) was increased. The induction of these p53 target
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genes following loss of HdmX was p53-dependent, as no increase in these p53 target
genes were observed after HdmX knockdown in two different p53-null tumor cell lines.
Cell cycle analysis and cell proliferation assays confirmed that the loss of HdmX led to a
significant G1 cell cycle arrest. Similar findings were observed upon Hdm2 knockdown,
and removing both HdmX and Hdm2 resulted in even greater p53 activation and a
synergistic or additive induction of p53 target genes associated with cell cycle arrest.
The increase in p53 transactivation following loss of HdmX was not due to p53
phosphorylation, suggesting a nongenotoxic or genotoxic stress independent p53
activation. Furthermore, the loss of HdmX did not appear to alter p53 localization or
stabilization. Although the removal of over-expressed HdmX appears limited to an antiproliferative effect in tumor cells harboring wild-type p53, loss of HdmX enhanced the
cytotoxicity of several chemotherapeutic agents. Cell viability assays showed an increase
in chemosensitivity in tumor cells following knockdown of HdmX and/or Hdm2. Taken
together, these results suggest that removal of HdmX may be an important therapeutic
target that would complement chemotherapy drugs currently used to treat tumors
possessing wild-type p53
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I. INTRODUCTION
A. p53 Structure and Function
The discovery of p53 in 1979 by two independent labs (Lane and Crawford, 1979;
Linzer and Levine, 1979) showed that the protein associated with the large T antigen in
SV40 transformed cells. Originally, p53 was believed to be a tumor antigen, and then an
oncogene since it was overexpressed in many human cancer cell lines (Crawford et al.,
1981). However, by the late 1980s the paradigm shifted and p53 was later confirmed a
tumor suppressor gene (Baker et al., 1990; Chen et al., 1990; Finlay et al., 1989; Mercer
et al., 1990; Vogelstein et al., 1989). The p53 tumor suppressor protein consists of 393
amino acid residues which can be divided into five domains. These domains include an
N-terminal transactivation domain (residues 1-43), a proline-rich region (residues 63-97),
a DNA binding domain (residues 102-292), a tetramerization domain (residues 323-356)
and a basic domain (residues 363-393) (Figure 1). The transactivation (TA) domain
interacts with transcriptional machinery and repair factor proteins (Ko and Prives, 1996).
The proline rich region binds signaling molecules which contribute to the pro-apoptotic
function of p53 (Gorina and Pavletich, 1996; Harms and Chen, 2006). The central DNA
binding domain of p53 is essential for its role as a sequence specific transcription factor.
The p53 responsive element contains two copies or half sites of a 10 base pair consensus
sequence, 5’-PuPuPuC(A/T)(T/A)GPyPyPy, which are separated by 0-13 base pairs (elDeiry et al., 1992). In order for p53 to be transcriptionally active and bind DNA, two p53
dimers must oligomerize through their tetramerization domains to form an active p53
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tetramer (McLure and Lee, 1998). A nuclear localization signal (NLS) is located at
residues 305-322 and the two nuclear export signals are located at residues 11-27 and
residues 340-351 (Harms and Chen, 2006). The C- terminal basic domain functions as a
regulatory domain, and has multiple functions including DNA binding and nuclear import
(Braithwaite et al., 2005; Liang and Clarke, 1999; Yakovleva et al., 2001).
The p53 protein is activated by a variety of genotoxic insults and cellular stresses.
Once activated, p53 functions as a transcription factor to modulate the expression of a
diverse array of downstream genes. These p53 target genes are involved in cell cycle
arrest (i.e. p21, GADD45, BTG2), DNA repair (i.e. PCNA, p48, p53R2) and apoptosis
(i.e. BAX, NOXA, PIG), and contribute to the tumor suppressor activity of p53 (Vousden
and Lu, 2002). Upon DNA damage or various types of cellular stress, p53 is stabilized
by post-translational modifications mainly within the N-terminal transactivation domain
or the C-terminal regulatory domain. Some of these modifications are known to disrupt
the interaction between p53 and its negative regulator, Hdm2 (Michael and Oren, 2003;
Unger et al., 1999) or to enhance tetramerization, stability or activity of p53 (Hirao et al.,
2000; Lavin and Gueven, 2006). Phosphorylations are the predominant post-translational
modification of the p53 transactivation domain and are brought about by a number of
protein kinases (Figure 1) (Meek, 2002). DNA damage caused by ionizing radiation
induces ATM (ataxia-telangiectasia, mutated) mediated phosphorylation either directly or
indirectly at serines 6, 15, 20 and 46 within the N-terminal domain of p53 (Canman et al.,
1998; Saito et al., 2002). Serines 6, 15 and 20 can also be phosphorylated by other
kinases, including ATR (A-T and Rad3-related), DNA-PK, and the checkpoint kinases,
Chk1 and Chk2 (Appella and Anderson, 2001). Serine 46, which has been reported to be
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Figure 1. Schematic diagram of p53 protein and select phosphorylation
sites. NLS, nuclear localization signal; NES, nuclear export signal; N-terminal
Transactivation domain (yellow) and C-terminal Basic domain (blue) showing
select phosphorylation sites (red circles) and the kinases responsible for
phorphorylating those sites (reviewed by Lavin and Gueven, 2006).
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important in regulating the ability of p53 to induce apoptosis is phosphorylated by HIPK2
(homedomain-interacting protein kinase 2) (Mayo et al., 2005; Oda et al., 2000b). In the
C-terminal domain of p53, phosphorylation of serine 392 by CAK (cyclin-activating
kinase) or CK2 has been reported to influence DNA binding, transcriptional activation
and the growth inhibition function of p53 (Kohn, 1999; Lu et al., 1998; Prives and Hall,
1999). Additional post-translational modifications in the C-terminal tetramerization and
regulatory domains include acetylation, neddylation, methylation and ubiquitination
(Lavin and Gueven, 2006).
Under most non-stress conditions, p53 protein is maintained at a low basal level
and p53 activity is tightly regulated by rapid p53 turnover. The N-terminal
transactivation domain of p53 interacts with its negative regulators, Hdm2 and HdmX
protein, which block p53 transactivation (Finch et al., 2002; Haupt et al., 1997; Kubbutat
et al., 1997). The stringent regulation of p53 involves a complex network of proteins,
and is critical for maintaining genomic stability and suppressing tumor formation. Hdm2
and its structural homologue, HdmX, represent two essential negative regulators of p53
(Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001).
B. Hdm2 and HdmX Structure and Function
Hdm2 and HdmX (human homologs of the murine double minute proteins, Mdm2
and MdmX, respectively) are both p53 binding proteins that are structurally similar and
share over 90% amino acid identity with their murine homologs (Shvarts et al., 1997).
The Hdm2 and HdmX proteins possess the greatest similarities in the N-terminal p53
binding region, the internal zinc finger, and the C-terminal RING (really interesting new
gene) finger domain (Figure 2) (Jackson et al., 2001; Shvarts et al., 1996).
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Figure 2.

Schematic diagram comparing Hdm2 and HdmX protein homology.

NLS, nuclear localization signal; NES, nuclear export signal; NoLS, nucleolar
localization signal. The greatest amino acid similarity between Hdm2 and HdmX is
found in the p53 binding domain, the Zinc (Zn) finger and the RING finger domain
(adapted from Jackson and Berberich, 2001).
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Both Mdm2 and MdmX act as critical negative regulators of p53 in vivo and the loss of
either Mdm2 or MdmX leads to embryonic lethality in knockout mice if not rescued by
the concurrent elimination of p53 (Finch et al., 2002; Jones et al., 1995; Montes de Oca
Luna et al., 1995; Parant et al., 2001). The embryonic lethality occurs at implantation in
mdm2-null embryos and at gastrulation for mdmX-null embryos, suggesting that Mdm2
and MdmX inhibit p53 function in a partially non-overlapping manner (Parant et al.,
2001). Using mouse models, the loss of Mdm2 was shown to induce p53 dependent
apoptosis, whereas the loss of MdmX led to a lack of cell proliferation in one model, and
to cell cycle arrest and apoptosis in another (Chavez-Reyes et al., 2003; Parant et al.,
2001; Xiong et al., 2006).
There are several other key differences between Hdm2 and HdmX that are critical
for understanding how these two proteins regulate p53. Hdm2 directly associates with
p53 resulting in inhibition of p53 transactivation (Oliner et al., 1993) and ubiquitination
of p53 protein targeting it for proteosomal degradation (Haupt et al., 1997; Honda et al.,
1997; Kubbutat et al., 1998; Moll and Petrenko, 2003). The evolutionarily conserved Cterminal RING finger domain of Hdm2 is critical for its E3 ubiquitin ligase activity, and
it serves to target its own ubiquitination and degradation as well (Fang et al., 2000).
Beside a fully functional RING finger domain, the central acidic domain of Hdm2 is
essential for p53 ubiquitination as assessed through a series of Hdm2-HdmX chimeric
proteins (Kawai et al., 2003b; Meulmeester et al., 2003). While HdmX shows
conservation in the E3 ligase RING finger domain with Hdm2, HdmX lacks E3 ligase
activity (Jackson and Berberich, 2000; Stad et al., 2001). Furthermore, Hdm2 and HdmX
contain a nucleolar localization signal (NoLS) within the RING domain (Jackson et al.,
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2001; Weber et al., 2000); however, HdmX does not possess nuclear localization or
export signals like Hdm2 (Jackson et al., 2001; Shvarts et al., 1996). Thus Hdm2 shuttles
back and forth between the nucleus and cytoplasm, while HdmX is predominantly
localized in the cytoplasm (Migliorini et al., 2002; Roth et al., 1998). Hdm2 and HdmX
can heterodimerize with each other through their conserved RING finger domains and
this interaction stimulates the recruitment of HdmX into the nucleus (Migliorini et al.,
2002; Tanimura et al., 1999). Additionally, the interaction between Hdm2 and HdmX
has been shown to stabilize Hdm2 by interfering with Hdm2 auto-ubiquitination, and
overexpression of HdmX stabilizes p53 by preventing Hdm2-mediated degradation of
p53 while suppressing its transactivation (Jackson and Berberich, 2000; Stad et al., 2001).
The regulation of p53 by Hdm2 and HdmX appears to involve cooperation between the
two proteins. Both Mdm2 and MdmX were found to be essential for regulating p53
activity in a nonredundant manner, whereby, Mdm2 regulated p53 protein levels and
MdmX fine-tuned p53 transcriptional activity (Francoz et al., 2006). The effect of Hdm2
and HdmX on p53 stability and activity is dependent on the relative abundance of Hdm2
and HdmX proteins. When HdmX levels are less than 2:1 with Hdm2, p53 stability is
decreased, whereas overexpressed HdmX increased p53 stability by competing with
Hdm2 for p53 binding (Gu et al., 2002; Mancini et al., 2004; Stad et al., 2001).
However, some in vitro studies have suggested that HdmX acts as a stimulator of Hdm2
E3 ligase activity and facilitates ubiquitination of p53 and itself (Linares et al., 2003).
Further evidence suggests that Hdm2 promotes ubiquitination and proteasomal
degradation of HdmX in addition to p53 and itself (de Graaf et al., 2003; Pan and Chen,
2003).
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Additionally, HdmX contains a caspase 3 cleavage site at residue 361 which is p53dependently cleaved by caspase following DNA damage (Gentiletti et al., 2002). The
larger truncated product is then degraded through the proteasomal pathway; however,
HdmX degradation by Hdm2 does not depend on caspase cleavage (Kawai et al., 2003a).
Taken together, the interactions between p53, Hdm2 and HdmX are critical for the
stringent control of p53 activity (Marine and Jochemsen, 2004).
C. Regulation of p53
The tumor suppressor protein, p53, undergoes constant ubiquitination and
proteasomal degradation in order to maintain low basal levels of p53 in non-stressed cells
(Kubbutat et al., 1997). However, ubiquitination of p53 is inhibited in response to
various stresses, leading to the accumulation and activation of p53, and induction of cell
cycle arrest and/or apoptosis (Ashcroft and Vousden, 1999). The half-life of p53 in
normal unstressed cells is approximately 30 minutes, but DNA damage increases the
half-life to several hours causing accumulation of p53 (Yang et al., 2004). The stability
of p53 is predominantly regulated by the action of Hdm2 which ubiquitinates p53 and
promotes its degradation through nuclear and cytoplasmic proteasomes (Haupt et al.,
1997; Kubbutat et al., 1998; Moll and Petrenko, 2003). Specifically, Hdm2 transfers
monoubiquitin moieties onto one or more lysine residues of p53, mainly in the C-terminal
region (Kubbutat et al., 1998; Rodriguez et al., 2000). Mutational analysis of six lysine
residues to arginine within the C-terminal portion of p53 decreased the susceptibility of
p53 to Hdm2-mediated degradation (Rodriguez et al., 2000). Additionally, the
tetramerization domain of p53 is required for efficient Hdm2 binding and ubiquitination
of p53 (Kubbutat et al., 1998; Maki, 1999). Recently it was shown that Hdm2 is capable
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of catalyzing both mono- and polyubiquitination of p53 depending on the level of Hdm2.
Low levels of Hdm2 induce monoubiquitination and nuclear export of p53, whereas p53
poly-ubiquitination and nuclear degradation is caused by high levels of Hdm2 (Brooks et
al., 2004; Li et al., 2003) . Furthermore, monoubiquitination appears to be critical for
p53 translocation out of the nucleus since a p53-ubiquitin fusion protein that mimics
monoubiquitinated p53 was found to accumulate in the cytoplasm independently of
Hdm2 (Brooks et al., 2004; Li et al., 2003). Other evidence suggests that Hdm2mediated p53 polyubiquitination takes place in a complex with p300/CREB-binding
protein (CBP) in the nucleus (Grossman et al., 2003). The intrinsic ubiquitin ligase
activities of both Hdm2 and p300 are believed to be necessary for the generation of
polyubiquitinated chains on p53 that target it for proteasomal degradation (Grossman et
al., 2003).
In addition to Hdm2, Pirh2 (p53 induced RING-h2) has also been identified as an
E3 ligase that physically interacts with p53 and promotes ubiquitination and proteasomal
degradation of p53 independently of Hdm2 (Leng et al., 2003). Pirh2 contains a RING
finger domain and is a p53 transcriptional target gene which participates in an autoregulatory feedback loop that modulates p53 stability (Leng et al., 2003). Another E3
ligase, COP1 (constitutively photomorphogenic 1), is also a RING finger containing
protein that causes p53 degradation through the proteasome in a ubiquitin-dependent
manner, independent of Hdm2 or Pirh2 (Dornan et al., 2004). Together, Hdm2, Pirh2,
and COP1 represent three ubiquitin ligases for p53 which the cell can utilize to maintain
tight control of the tumor suppressor.
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D. p53-Hdm2 Auto-regulatory Feedback Loop
Upon DNA damage, p53 is activated leading to the transcriptional activation of a
diverse array of p53 target genes. Hdm2 is a p53 target gene which encodes a protein
that directly binds p53 and inhibits its activity, thereby forming a negative autoregulatory feedback loop (Figure 3) (Momand et al., 1992; Wu et al., 1993). The p53Hdm2 feedback loop is further regulated by a network of other proteins which interact
with p53 and/or Hdm2. One of these proteins is HdmX which directly associates with the
transactivation domain of p53 and inhibits its activity (Shvarts et al., 1996). The
phosphorylation of HdmX on serine 289 by casein kinase 1 alpha enhances its binding to
p53 (Chen et al., 2005b) and this p53-HdmX interaction inhibits p300/CBP mediated
acetylation of p53 (Sabbatini and McCormick, 2002). Similarly, Hdm2 interaction with
p53 also inhibits p300-mediated acetylation of p53 (Kobet et al., 2000).
Upon DNA damage, Hdm2 mediates the ubiquitination and degradation of HdmX
to facilitate p53 activation (de Graaf et al., 2003; Pan and Chen, 2003). The Hdm2mediated ubiquitination of HdmX is dependent on functional nuclear ATM and
phosphorylation on at least three sites on HdmX (Pereg et al., 2005). ATM directly
targets S403, whereas Chk2 kinase is required for phosphorylation of MdmX on S342
and S367 (Chen et al., 2005a; Okamoto et al., 2005). Furthermore, phosphorylation of
S367 is required for 14-3-3 binding to HdmX, which facilitates HdmX nuclear import
and degradation by Hdm2 (LeBron et al., 2006). Taken together, phosphorylation of
HdmX after DNA damage redirects the E3 ligase activity of Hdm2 towards HdmX
instead of p53 leading to p53 activation (Chen et al., 2005a).
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Figure 3. p53-Hdm2 negative feedback loop. Upon DNA damage, p53 is activated
and p53 responsive genes are induced. Hdm2 is a p53 target gene which encodes a
protein that directly binds p53 leading to inhibition of p53 transcriptional activity and
Hdm2 mediated ubiquitination and proteasomal degradation; thus forming a negative
feedback loop. HdmX and ARF can also impact the p53-Hdm2 feedback loop.
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Post translational modifications of Hdm2 also contribute to its ability to associate
with and ubiquitinate p53, HdmX or itself (Khosravi et al., 1999). In response to specific
DNA damaging agents, ATM phosphorylates Hdm2 on serine 395 which appears to
destabilize its interaction with p53 and inhibit the nuclear-cytoplasmic shuttling of p53
(Maya et al., 2001). Sumoylation of Hdm2 and HdmX, modification by SUMO (a small
ubiquitin-like modifier), can also affect stability and protein-protein interactions, by
decreasing Hdm2-mediated ubiquitination (Buschmann et al., 2001; Ghosh et al., 2005).
Thus, the numerous post-translational modifications of p53, Hdm2 and HdmX add
another layer of complexity to the p53-Hdm2 auto-regulatory feedback loop.
Other proteins which participate in the control of p53 activity include HAUSP
(herpes virus-associated ubiquitin specific protease) which directly interacts with and
deubiquitinates p53, Hdm2 and HdmX leading to stabilization of each protein (Hu et al.,
2006b; Li et al., 2004; Li et al., 2002). ATM-dependent phosphorylation of Hdm2 and
HdmX decreases their affinity for HAUSP resulting in the destabilization of Hdm2 and
HdmX and activation of p53 (Meulmeester et al., 2005). The p14ARF (alternative
reading frame protein expressed from the INK4A locus) protein also binds to Hdm2 and
HdmX, sequestering these proteins within the nucleolus so that p53 can be activated
(Jackson et al., 2001; Tao and Levine, 1999; Weber et al., 2000; Weber et al., 1999). The
protein-protein interactions presented here are a few of the key players involved in the
regulation of the p53-Hdm2 feedback loop.
E. p53 and Cancer
Mutations in the p53 tumor suppressor gene are among the most prevalent
molecular abnormalities in human cancer. Half of all human tumors possess mutations in
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p53 (Hollstein et al., 1996), which usually disrupts the ability of p53 to bind DNA and
function as a transcription factor. The majority of tumor-derived mutations are missense
mutations that can be classified as either contact site (hotspot mutations: R248 and R273)
or conformational (hotspot mutations: R175, G245, R249, and R282) mutations.
Mutation at a residue that is critical for p53-DNA interaction is categorized as a contact
site mutation, whereas conformational mutations fail to stabilize the p53 protein
necessary for proper binding to DNA (Harms and Chen, 2006). Studies conducted in
mice with mutated or genetically deficient p53 were found to be extremely prone to
tumor formation (Donehower et al., 1992). Furthermore, germ line mutations in p53 lead
to the inherited cancer predisposing condition in humans, Li-Fraumeni Syndrome (Li et
al., 1988; Malkin et al., 1990). These findings indicate the importance of p53 in
suppressing tumor formation and protecting the genome.
While half of all human tumors contain mutations in the p53 gene, inactivation of
wild-type p53 protein can also occur through a variety of mechanisms. The inactivation
of p53 can occur by either overexpression or deregulation of proteins that are critical for
controlling the p53 pathway. Overexpression of HdmX or Hdm2 can occur as a result of
gene amplification, enhanced transcription, or increased translation (Oliner et al., 1992;
Ramos et al., 2001; Riemenschneider et al., 1999). Furthermore, deletion or silencing of
the INK4a locus that encodes p14ARF can lead to elevated levels of Hdm2 since ARF
would not be present to inactivate Hdm2 (Lowe and Sherr, 2003). Increased Hdm2
transcription due to a single nucleotide polymorphism (SNP) in the Hdm2 promoter can
also result in increased levels of Hdm2 (Bond et al., 2004). The overexpression of either
HdmX or Hdm2 can inhibit the activity of p53 and directly contribute to tumor
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formation. Thus it is not surprising that elevated levels of one or both of these proteins
are found in many human tumors and tumor cell lines which harbor wild-type p53
(Toledo and Wahl, 2006).
F. Role of HdmX and Hdm2 in Cancer
In approximately 30% of tumor cell lines retaining wild-type p53, HdmX and/or
Hdm2 were overexpressed or HdmX was expressed as a shorter protein (Ramos et al.,
2001). Recent analysis of a large set of tumors showed amplified hdmX expression in
19% of breast carcinomas, 19% of colon cancer, 18% of lung cancer (Danovi et al., 2004)
and 65% of human retinoblastomas (Laurie et al., 2006). Overall, approximately 17% of
all human tumors have overexpressed HdmX (Toledo and Wahl, 2006) and the majority
of these possess wild-type p53. The overexpression of MdmX in mouse embryonic
fibroblasts immortalizes the cells and with an activated RasV12, HdmX transforms
primary cells (Danovi et al., 2004). These results suggest that HdmX may function as an
oncogene when amplified or constitutively overexpressed, leading to tumor formation.
Additionally, many tumor cell lines harbor an HdmX splicing variant, HdmX-S (HdmX
short form, amino acid 1-114), which appears to be very stable and capable of binding to
p53 more efficiently than the full length HdmX (Rallapalli et al., 1999; Rallapalli et al.,
2003). Another aberrantly spliced form of HdmX lacking the p53 binding domain,
HdmX211, was isolated from a thyroid tumor cell line. HdmX211 stabilized p53 by
associating with Hdm2 and inhibiting Hdm2-mediated degradation of p53 without
disrupting the Hdm2-p53 interaction thereby resulting in transcriptionally inactive p53
(Giglio et al., 2005). These HdmX splice variants are very powerful inhibitors of p53
transactivation, thus a cancer therapeutic that can effectively down regulate both full
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length HdmX and the aberrantly spliced forms of HdmX may represent an important
molecular target.
Diverse approaches to activate the wild-type p53 in tumors with overexpressed
HdmX and/or Hdm2 include the use of small molecule antagonists such as Nutlin or
RITA to inhibit the Hdm2-p53 interaction (Issaeva et al., 2004; Kojima et al., 2005;
Patton et al., 2006; Vassilev, 2004), the use of antisense oligonucleotides, antibodies and
small interfering RNAs directed at Hdm2 or HdmX (Chene, 2003; Linares and Scheffner,
2003; Zhang et al., 2005), and the use of compounds to inhibit the E3 ligase activity of
Hdm2 (Yang et al., 2005). Both the Nutlin compounds and RITA are very effective at
disrupting the Hdm2-p53 interaction leading to p53 activation and toxicity in tumor cell
lines and xenograft tumors in mice (Issaeva et al., 2004; Vassilev et al., 2004). The
activation of p53 by Nutlin does not induce phosphorylation of p53 on any of the six
major serine sites (Thompson et al., 2004), suggesting that p53 phosphorylation is not
required for activation of p53, induction of p53 target genes or a biological response.
Furthermore, the combination treatment of Nutlin with either etoposide or cisplatin
dramatically enhanced the activity of genotoxic agents in neuroblastoma (Barbieri et al.,
2006). Another recent study using Nutlin and various chemotherapy drugs reported that
nongenotoxic p53 activation resulting from blocking Mdm2-p53 association led to
increased chemosensitivity to DNA damaging agents but not chemotherapy agents that
work by inhibiting DNA replication (Kranz and Dobbelstein, 2006). However, these
small molecule antagonists are not effective at disrupting the HdmX-p53 interaction,
therefore, tumors with high levels of HdmX are resistant to Nutlin leading to the
continued suppression of p53 activity (Patton et al., 2006). These findings suggest that
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Hdm2 and HdmX are specific independent therapeutic targets for activating wild-type
p53 and anti-cancer approaches that target both Hdm2 and HdmX should be considered
as a means of treatment for tumors (Patton et al., 2006; Toledo et al., 2006).
The utilization of siRNA to knockdown endogenous HdmX expression in tumor
cell lines with overexpressed HdmX and wild-type p53 has gained popularity. However,
the conflicting data from these studies have been difficult to reconcile. The knockdown
of HdmX inU2OS cells resulted in decreased Hdm2 and increased p53 levels in one study
(Gu et al., 2002), while others reported that reduction of HdmX expression in U2OS and
MCF7 cells increased both Hdm2 and p53 levels (Linares et al., 2003). Still others have
observed no significant effect on Hdm2 and p53 levels after partial loss of HdmX by
siRNA in MCF7 cells (Danovi et al., 2004). However, the down regulation of HdmX
consistently resulted in an increased expression of p53 target genes (e.g. p21) in all these
studies, despite the presence or absence of alterations in p53 protein levels.
Furthermore, the removal of HdmX in tumors with overexpressed HdmX sensitized these
cells to p53-dependent apoptosis or cell cycle arrest in response to Nutlin treatment
(Patton et al., 2006). The knockdown of Hdm2 by siRNA in a colorectal adenocarcinoma
cell line inhibited cell growth and tumor formation, and enhanced the chemosensitivity to
cisplatin (Yu et al., 2006). Thus, the removal of Hdm2 and/or HdmX in tumors with
wild-type p53 and overexpressed Hdms by siRNA appears to be a viable option for
cancer therapy.
G. RNA Interference
RNA interference (RNAi) is a naturally occurring process for sequence specific silencing
of genes post transcriptionally. It is a highly conserved mechanism the cell uses to
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defend the genome from viruses. RNAi was first reported in 1998 in C. elegans after
injection with double-stranded RNA (dsRNA) (Fire et al., 1998). The dsRNA molecules
are recognized by the cell and cleaved by the cytoplasmic ribonuclease Dicer, into
siRNAs containing 21-23 nucleotides. The siRNA molecules are incorporated into a
multiprotein RNA-induced silencing complex (RISC) which guides its cleavage of
complementary mRNA (Figure 4) (Dykxhoorn et al., 2003; Meister and Tuschl, 2004;
Sandy et al., 2005). Assessing the function of a gene by silencing its transcript has
become a common practice. Although there are numerous methods that can successfully
be employed to silence a gene, including synthetic siRNAs, expression vectors with short
hairpin RNAs, viral vectors and in vitro transcribed siRNA (Elbashir et al., 2001a;
Elbashir et al., 2001b; Katoh et al., 2003; Liu et al., 2004; Paddison et al., 2002), they do
not always yield the same result. Thus, it is critical to understand that RNAi may nonspecifically target unrelated genes, altering their expression and possibly leading to an
unexpected or even cytotoxic phenotype (Fedorov et al., 2006; Fish and Kruithof, 2004;
Jackson et al., 2003). Some of these non-specific effects can be explained by the
induction of an interferon response triggered by the processing of shRNA vectors in the
cell (Bridge et al., 2003; Sledz et al., 2003) or by viral infection (Stark et al., 1998).
However, the activation of unexpected non-targeted genes can also occur in the absence
of an interferon response (Scacheri et al., 2004) or in tumor cells that have a defective
interferon response (Stojdl et al., 2000). It is speculated that partial complementary
sequence matches between the siRNA and the off-target genes may account for some
gene expression alterations (Lin et al., 2005), thus using the lowest effective dose of
siRNA and using different siRNA target sequences for your gene of interest will decrease
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the likelihood of an off-target gene being altered. Although the art of designing effective
and specific siRNAs has advanced greatly over recent years (Birmingham et al., 2006;
Braasch et al., 2003; Jackson et al., 2006), new concerns regarding the therapeutic
potential of RNAi have arisen. These concerns include renal excretion of unmodified
circulating siRNA, rapid degradation by intracellular and extracellular nucleases, and
delivery of the siRNA to the target organ(s) (reviewed by Lee and Sinko, 2006). Some of
these concerns have been eliminated by incorporating siRNA into particles, conjugating
the siRNA to a transporter, such as cholesterol, or using the specificity of an antibody to
deliver the siRNA to the target cells (Dykxhoorn and Lieberman, 2006). Modified
siRNA targeting vascular endothelial growth factor (VEGF) effectively inhibited tumor
growth in mice when injected locally into subcutaneous tumors (Kim et al., 2006; Takei
et al., 2004).
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Figure 4. Mechanism of RNAi. The diagram illustrates five methods for producing
siRNAs; (A) chemical synthesis, (B) digestion by Dicer, (C) in vitro transcription, (D)
plasmid/viral expression vectors, and (E) PCR expression cassette. The siRNA is
incorporated into RISC, and binds and cleaves the target mRNA (www.dharmacon.com).
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H. Rationale for Study
The p53 tumor suppressor protein must be tightly regulated since either a gain or
loss of activity can have serious physiological consequences. Hdm2 is thought to be the
primary regulator of p53 and the p53-Hdm2 negative feedback loop is well established.
However, the role of HdmX in the regulation of p53 and Hdm2 is still controversial and
further studies are needed to specifically elucidate its function(s) in the regulation of the
p53 pathway and in tumorgenesis. Since the discovery of HdmX in 1996 as a p53
binding protein with significant homology to Hdm2, research into HdmX activities has
led to the conclusion that it is an essential negative regulator of p53. The importance of
HdmX was demonstrated by the embryonic lethality of MdmX knockout mice, and more
recently by the discovery that 17% of human tumors overexpress HdmX, with the
majority harboring wild-type p53. Thus, this dissertation research takes an in depth look
at the alterations in global gene expression and the biological effects of silencing HdmX
and/or Hdm2 in tumor cell lines with wild-type p53. My hypothesis is that loss of HdmX
in tumors with wild-type p53 and overexpressed HdmX will activate p53 and p53 target
genes, leading to growth inhibition. Since HdmX binds directly to p53 and Hdm2, this
study also examines how HdmX knockdown affects p53 and Hdm2 localization and
stabilization. Furthermore, this study investigates how the elimination of HdmX affects
the sensitivity of the tumor cells to chemotherapeutic agents. As shown with Nutlin, a
small molecule that inhibits p53-Mdm2 interaction, the removal of HdmX enhances the
p53-dependent cytotoxicity of Nutlin indicating that HdmX is a key therapeutic target
that can complement chemotherapy drugs currently used to treat tumors with wild-type
p53.

20

II. MATERIALS AND METHODS
A. Cell Lines, Antibodies, and Reagents
The human tumor cell lines, MCF7 (breast carcinoma), HCT116-p53+/+
and HCT116-p53-/- (colorectal carcinoma), U2OS (osteosarcoma), U87 (glioblastoma),
H1299 (non-small cell lung carcinoma) and SAOS (osteosarcoma) were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM; Cellgro) supplemented with 10% bovine
growth serum (BGS; Hyclone), and 10 µg/mL gentamicin unless otherwise indicated.
The diploid human fibroblast cell line, IMR90 (ATCC) was grown in DMEM
supplemented with 10% fetal bovine serum (FBS; Gibco), and 10 µg/mL gentamicin
unless otherwise indicated. HdmX (Bethyl Laboratories, Inc.), p21, (C-19, Santa Cruz
Biotechnology, Inc.), and BAX, (Ab-1, Calbiochem) polyclonal antibodies, and
monoclonal p53 antibody (Ab-6, Oncogene), Hdm2 antibody (SMP-14, Santa Cruz
Biotechnology, Inc.) and beta-actin antibody (Sigma, Inc.) were used as indicated. A
phosphorylation-specific p53 polyclonal antibody kit (Cell Signaling Technology, Inc.)
was utilized per manufacturer’s protocol. Horseradish peroxidase (HRP)-conjugated
anti-mouse or anti-rabbit secondary antibodies (Promega) were used with Super Signal
substrate (Pierce) for chemi-luminescence detection of proteins. siGENOME duplex
RNA targeting hdmX, hdm2, p53, and a non-targeting control siRNA (5’UAGCGACUAAACACAUCAAUU) were obtained from Dharmacon Research, Inc. and
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a 20 µM stock solution was prepared according to manufacturer’s protocol. siRNA
aliquots were stored at -20oC and used within three freeze thaw cycles. The siRNA
transfection was performed using either Oligofectamine (Invitrogen) or Lipofectamine
2000 (Invitrogen) as described below. To optimize siRNA transfection efficiency,
siTOX (Dharmacon Research, Inc.) was employed. Doxorubicin hydrochloride (Tocris
Bioscience) was prepared as a 5 mg/mL stock solution in water. Cytosine β-Darabinofuranoside (Sigma, Inc.) was prepared as a 10 mM stock in DMSO and cisdiammine platinum (II) dichloride (Sigma, Inc.) was prepared as a 25 mM stock solution
+2

in Dulbecco’s phosphate buffered saline (DPBS) containing Ca

+2

and Mg .

Recombinant human Interferon-gamma (IFN-γ) was purchased from R & D Systems.
B. siRNA Transfection
Cells were either triple transfected with siRNA on three consecutive days post
seeding, or reverse transfected at the time of seeding plus transfected again 24 hours later
(Figure 5). Cells were seeded at 200,000 cells per well in 6-well plates (for RNA
isolation), or at 700,000 cells per 6-cm dish (for protein extraction) in antibiotic free
DMEM. For triple transfection, cells were plated 24 hours prior to the first siRNA
transfection. Dilutions of the Oligofectamine and siRNA stock solutions were prepared
as follows immediately prior to transfection (Table 1). For each well of a 6-well plate, 3
µL of Oligofectamine was diluted with 112 µL serum free media (SFM) and allowed to
incubate at room temperature for 10 minutes. 5 µL of siRNA was mixed with 180 µL
SFM, and then it was added to the tube containing the diluted Oligofectamine. The
mixture was allowed to incubate for 20-30 minutes at room temperature. The cells were
washed once in SFM, and then 700 µL SFM was added to each well of a 6-well plate.
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The 300 µL of siRNA/Oligofectamine mixture was added to each well for a final
concentration of 100 nM siRNA (Dharmacon Research, Inc.) per well. The volumes of
Oligofectamine, siRNA, and SFM were adjusted appropriately for transfection in a 6-cm
dish so that the final concentration of siRNA was 100 nM and the final volume was 1.5
mL/dish (Table 1). After a four hour incubation at 37oC in a 5% CO2 incubator, 1 mL (or
an equal volume) of DMEM containing 20% BGS was added to each well without
removing the transfection mixture. The siRNA transfection was repeated a second and
third time at 24 and 48 hours following the first transfection, respectively.
For reverse transfection, the cells were transfected with 100 nM siRNA at the
time of seeding using Lipofectamine 2000 (Invitrogen) in a small volume of antibiotic
free DMEM containing 1% BGS. After a five hour incubation, the media was removed
and cells were refed with DMEM containing 10% BGS. Twenty hours later, the cells
were transfected a second time with siRNA in SFM using Oligofectamine as indicated
above for the triple transfection. After a four hour incubation, an equal volume of
DMEM containing 20% BGS was added to each well or dish without removing the
transfection mixture. Total RNA was isolated 24 hours following the last siRNA
transfection and protein was extracted at 48 hours following the last siRNA transfection
unless otherwise indicated.
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Figure 5. Timeline of siRNA transfections in human tumor cell lines.
(A) The triple transfection method involves transfecting the cells with siRNA on
three consecutive days 24 hours post seeding. (B) The reverse transfection
method involves seeding the cells with the siRNA:lipid mixture and then
transfecting the adherent cells a second time 24 hours later.
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24-well plate

6-well plate

6-cm dish

Cell
Number

100,000/well

200,000/well

700,000/dish

Volume of
siRNA +SFM

2.5 µL siRNA +
182.5 µL SFM

5 µL siRNA +
180 µL SFM

7.5 µL siRNA +
177.5 µL SFM

Volume of
Oligofectamine + SFM

1.5 µL lipid +
113.5 µL SFM

3 µL lipid +
112 µL SFM

4.5 µL lipid +
110.5 µL SFM

Total Volume

0.5 mL

1.0 mL

1.5 mL

Table 1. Volumes of siRNA, lipid, and serum free media (SFM) for siRNA
transfections. The table lists the appropriate volumes of each component necessary to
setup a 100 nM siRNA transfection in the various cell culture vessels.
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C. shRNA Lentivirus Generation and Infection
Complementary DNA oligonucleotides were designed, synthesized and annealed
to generate a double-stranded oligonucleotide (ds oligo). The ds oligonucleotides contain
a 21 nucleotide target sequence, a four nucleotide loop sequence (GAGA), a 21
nucleotide sequence that is the reverse complement of the target sequence, and a four
nucleotide 5’ overhang sequence required to facilitate directional cloning (Figure 6). The
double stranded oligonucleotides (5’-CACCGCAGTTAGGTGTTGGAATATTGAGAAATATTCCAACACCTAACTGC), HdmX sequence underlined) targeting HdmX and
lacZ (5’-CACCAAATCGCTGATTTGTGTAGTCGGAGACGACTACACAAATCAGCGA) were cloned into the pENTR™/H1/TO vector (Invitrogen) using T4 DNA Ligase
per manufacturer’s protocol. The ligation reaction was transformed into E coli,
kanamycin-resistant transformants were selected, and colonies were analyzed for the
desired entry clone. The resulting RNAi cassette was transferred from the entry clones
into either the pLenti4/BLOCK-iT™-DEST vector (Invitrogen) containing the Zeocin™
resistance gene, or the pLenti6/BLOCK-iT™-DEST vector (Invitrogen) containing the
Blasticidin resistance gene via a LR clonase recombination reaction per manufacturer’s
protocol. The recombination reaction was transformed into E.coli, and ampicillinresistant transformants were selected. The plasmid DNA was isolated using the Qiagen
Maxi-prep method, quantified via absorbance spectroscopy at 260 nm, and the expression
constructs were sequenced to verify that the RNAi cassette transferred properly. The
pLenti/ BLOCK-iT™-shRNA expression constructs were then packaged into replication
incompetent lentivirus by co-transfecting the pLenti-shRNA constructs and ViraPower™
packaging plasmids (Invitrogen) into 293FT cells per manufacturer’s protocol using
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Lipofectamine 2000 (Figure 7). The Lentivirus containing supernatants from the
transduced 293FT cells were collected 60 hours later and the cellular debris was removed
by centrifugation. The viral supernatant was aliquoted into 1 mL cryovials and stored at 80oC. Viral titers were determined by preparing 10-fold dilutions of the lentiviral stocks,
transducing the different dilutions of lentivirus into NIH3T3 cells, selecting for stably
transduced cells using the appropriate selection agent, staining cells with 1% crystal
violet and counting the number of antibiotic-resistant colonies in each dilution. Our viral
4

titers were typically between 10 – 106 plaque forming units (PFU) per mL.
The tumor cells were seeded at 200,000 cells per 6-cm dish 24 hours prior to
infection with the shRNA containing lentivirus. The lentiviral supernatant was thawed
and diluted in a small volume of antibiotic free media containing 10%BGS and 6µg/mL
Polybrene®. The media was removed from the cells and 1.5 mL of diluted virus was
added to the 6-cm dish to achieve a MOI (multiplicity of infection) of at least two. After
incubation at 37oC for 18 hours, the media containing virus was removed and replaced
with fresh, complete media. The appropriate antibiotic selection was applied 24 hours
later and continued for six to ten days until a control plate of non-transduced cells had all
died. Blasticidin and Zeocin™ (Invitrogen) kill curves were performed to determine the
lowest effective dose for selection in each of the tumor cell lines used (Table 2).
shRNA

Additionally, the pLenti6-GW/U6-lamin

control plasmid (Invitrogen) was packaged

into lentivirus as previously described and used as an additional control. Antibiotic
resistant cells were harvested for total RNA or protein at the time points indicated.
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Figure 6. Design of double-stranded oligonucleotide. The ds oligos contain a
5’ linker for directional cloning into the entry vector, a 21 nucleotide sense
sequence, a four nucleotide loop sequence and a 21 nucleotide antisense sequence.
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Cells

Zeocin™

Blasticidin

MCF7

750 µg/mL

6 µg/mL

U2OS

500 µg/mL

6 µg/mL

U87

n/a

4-6 µg/mL

HCT116-p53+/+

50 µg/mL

10 µg/mL

HCT116-p53-/-

25 µg/mL

8 µg/mL

Table 2. Dose of antibiotics used for selection. The table shows
the lowest effective dose of antibiotic that was used for the
selection of cells expressing the shRNA lentivirus vector.
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A

B

Infect tumor cells

Figure 7. Preparation of shRNA expressing lentivirus. (A) Preparation of
entry clone. (B) LR recombination reaction between entry construct and
pLenti/BLOCK-iT™ destination construct. (adapted from www.invitrogen.com).
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D. Affymetrix GeneChip Sample Preparation, Hybridization, and Scanning
MCF7 cells were seeded at 200,000 cells/well in 6-well plates 24 hours prior to
siRNA triple transfection. Each treatment condition; mock, siControl, siHdmX, siHdm2,
sip53 and siHdmX+sip53, was set up in triplicate and transfected as previously described.
Twenty four hours following the third transfection, cells were rinsed once with DPBS and
then 350 µL RLT lysis buffer (Qiagen) containing 1% β-Mercaptoethanol (β-ME) was
added directly to the wells. The lysate was transferred to a sterile RNase-free 1.7 mL
Eppendorf tube and total RNA was isolated using the RNeasy® Mini Kit (Qiagen) per
manufacturer’s protocol. The RNA was eluted from the RNeasy® spin column with 30
µL sterile RNase-free water. The RNA integrity and quantification were determined on
the Agilent 2100 Bioanalyzer using the RNA6000 Nano Labchip® according to
manufacturer’s protocol. A small amount of the RNA was diluted 1:10 in RNase-free
water prior to loading on the Nano Labchip® in order to obtain a concentration within the
25-500 ng range of the bioanalyzer.
First strand cDNA synthesis was performed with 5 µg of total RNA, 2 µL of 50
µM T7-Oligo(dT) Primer, 7 µL of First-Strand Master Mix and 1 µL of SuperScript II
enzyme per the One-Cycle cDNA Synthesis Kit (Affymetrix) protocol. Eukaryotic PolyA RNA controls (Affymetrix) were also included in the cDNA synthesis reaction as
quality control markers for the length and quantity of cDNA produced. RNase Hdependent second strand cDNA synthesis was performed using 10 units of DNA ligase
and 40 units of DNA Polymerase I according to the One-Cycle cDNA Synthesis Kit
(Affymetrix) protocol. The double-stranded cDNA was purified using the GeneChip
Sample Cleanup Module (Affymetrix) per manufacturer’s protocol. Biotin-labeled
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cRNA was synthesized using the GeneChip IVT Labeling Kit (Affymetrix) according to
the manufacturer’s protocol, utilizing T7 RNA polymerase and biotinylated nucleotides
to produce labeled single stranded cRNA. The cRNA was purified using the GeneChip
Sample Cleanup Module (Affymetrix) in order to remove unincorporated NTPs so that
the concentration of cRNA can be accurately determined. The cRNA was eluted from
the spin column in 40 µL RNase-free water, and then a small aliquot was diluted 1:10 in
RNase-free water for analysis on the Agilent 2100 Bioanalyzer as previously described.
Twenty micrograms of cRNA was fragmented by incubating the cRNA in Fragmentation
Buffer (Affymetrix) that has been optimized to cleave full-length cRNA into 35 to 200
base fragments by metal-induced hydrolysis at 94oC for 35 minutes. A small aliquot of
the fragmented cRNA was analyzed on the Agilent Bioanalyzer to confirm that the cRNA
was properly fragmented.
Fifteen micrograms of fragmented cRNA along with GeneChip Eukaryotic
Hybridization Controls (Affymetrix) were hybridized to the GeneChip® Human Genome
U133 Plus 2.0 Array (Affymetrix) containing over 47,000 transcripts and variants,
representing approximately 39,000 human genes. The probe arrays were filled with 200
µL of hybridization cocktail per manufacturer’s suggestion and hybridization was
performed for 16 hours in an Affymetrix GeneChip Hybridization Oven 640 at 45oC
under constant rotation at 60 rpm. The GeneChips were subjected to multiple washing
and staining cycles on the Affymetrix GeneChip Fluidics Station 450 using the EukGEWS2v5 protocol. Immediately after staining, the GeneChips were scanned at 570 nm on
an Affymetrix Scanner 3000 following protocols developed by Affymetrix for the HGU133 Plus 2.0 Array (Figure 8). The digitized images from the scanned chips were
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processed using Affymetrix GCOS software and global GeneChip scaling to a target
intensity value of 150.
E. Analysis of GeneChip Data
Each siRNA transfection condition was performed in triplicate and the RNA
samples were prepared individually for hybridization to three separate Affymetrix HGU133 Plus 2.0 Arrays. All analyses of the GeneChip data were performed using
Affymetrix MAS 5.0 and GeneSpring version 7.3 software. To determine which genes
were altered following knockdown of HdmX, Hdm2, p53, or the combination of
HdmX+p53, the following data mining approach was employed. The Affymetrix CHP
files were imported into GeneSpring. In GeneSpring the chips were normalized to the
fiftieth percentile and each gene normalized to its median relative expression. Next gene
lists were created containing those genes which show a 2-fold increase or greater relative
to siControl, or at least a 50% decrease relative to siControl. Additionally, only those
genes that were identified as being present or marginal in at least two of the three
replicates in the condition where expression is expected were included in the lists. Based
on these criteria, 364 genes were induced and 188 genes were suppressed following
knockdown of HdmX. To identify common genes between two lists (i.e. siHdmX and
siHdm2), Venn diagrams were utilized in GeneSpring, and Ingenuity Pathway Analysis
software was used to create pathway maps of interacting genes.
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Figure 8. Affymetrix GeneChip® Protocol. (A) Preparation of
fragmented, biotinylated cRNA. (B) GeneChip hybridization, staining, and
washing. (C) A representative image of scanned GeneChip.
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F. Quantitative RT-PCR
Cells were rinsed once in DPBS, lysed directly in the culture dish with RLT
buffer as previously indicated, and total RNA was isolated using the RNeasy® Mini Kit
(Qiagen) according to manufacturer’s protocol. The RNA was quantified by absorbance
at 260 nm (A260) by diluting 2 µL of the RNA in 98 µL TE (10 mM Tris-Cl, 1 mM
EDTA, pH 8.0), transferring the solution to a quartz cuvette and measuring the
absorbance on a spectrophotometer relative to a TE blank. The RNA concentration was
determined in µg/µL by the following equation: [RNA] = (40 µg/mL)( A260)(dilution
factor) (1mL/1000µL) assuming that an A260 of 1 corresponded to 40 µg of RNA per mL.
The purity of the RNA was estimated by the ratio of the absorbance at 260 nm and 280
nm (A260/A280), with pure RNA having a ratio of 1.8-2.1. Each RNA sample was
individually reverse transcribed with random hexamers to create cDNA using the
TaqMan Reverse Transcription Kit (Applied Biosystems) per manufacturer’s protocol.
Briefly, 1 µg of RNA was mixed with 2.5 µL of 10X TaqMan RT buffer, 5.5 µL of 25
mM MgCl2, 5.0 µL of deoxyNTPs, 1.25 µL of random hexamers, 0.5 µL of RNase
inhibitor, 0.625 µL of Multiscribe reverse transcriptase, and RNase-free water for a total
reaction volume of 25 µL. The reverse transcription (RT) reaction was performed in a
Perkin Elmer Gene Amp PCR System 2400 programmed to sequentially cycle as follows:
initial 10 minute incubation at 25oC, 30 minute RT step at 48oC, 5 minute inactivation
step at 95oC, and an infinite hold at 4oC. After RT reaction was complete, cDNA was
diluted 1:2 by adding 25 µL sterile DNAse-free water to each sample prior to storage at
-20oC.
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Quantitative real-time PCR was performed in a 96-well microtiter plate format on
an ABI Prism 7900HT sequence detection system. A 20 µL reaction was prepared by
mixing 1µL of cDNA, 8 µL of DNAse-free water, 10 µL of 2X TaqMan Universal PCR
master mix, and 1 µL of Assay-on-Demand Gene Expression product (Applied
Biosystems, containing forward and reverse primers and a fluorescent Taqman probe)
designed and optimized for gene of interest, to each well on the 96-well plate. The PCR
conditions include a 2 minute hold at 50oC, a 10 minute hold at 95oC, and 40 cycles of a
15 second 95oC denaturing step and a 1 minute 60oC anneal and elongation step. Each
cDNA sample was separately analyzed in triplicate for target gene and GAPDH, and the
fold change (RQ value) relative to the control sample was calculated based on a PCR
efficiency of two and normalized to GAPDH (endogenous control) RNA levels using
SDS 2.0 software (ABI). Outlier cycle threshold (CT) values were eliminated and
defined as being a least one full CT from the mean value of the other two replicates. The
mean RQ values are plotted and the error bars represent the standard deviation of 6-9
reactions per RNAi treatment condition.
G. Western Blot Analysis
Cells were harvested following selection or at 48 hours post siRNA transfection
unless otherwise indicated. The media was removed and the cells were washed once with
cold DPBS. A volume of 1 mL of cold DPBS was added to each 6-cm dish, the cells
were scraped from the dish, transferred to a sterile 1.7 mL Eppendorf tube and
centrifuged for 5 minutes at 2000 rpm to pellet the cells. The DPBS was aspirated and
the cell pellet was frozen at -80oC overnight. A whole cell extract was prepared by
thawing the cells on ice and resuspending the cell pellet in 150 µL cold Giordano’s
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buffer (Mancini et al., 2004) composed of 50 mM Tris-HCl, pH 7.4, 0.25 M NaCl, 0.1%
Triton X-100, 5 mM EDTA, and 1% protease inhibitor cocktail (Sigma) by pipetting up
and down to lyse the cells. The cell suspension was placed on ice for 40 minutes to allow
complete protein extraction, centrifuged for 10 minutes at 10,000 rpm, and the soluble
protein fraction was transferred to a separate tube. Alternatively, the cells were lysed
directly in the dish by adding 250 µL of phosphatase inhibitor extraction buffer (120 mM
NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EGTA, 1 mM EDTA, 5 mM NaPPi, 10 mM
NaF, 30 mM p-nitrophenyl phosphate disodium salt (Pierce), 1 mM Benzamidine, 0.1%
NP-40 (Ipegal Ca-630), 0.2 mM PMSF, and 1% protease inhibitor cocktail) to each dish
and allowing it to sit on ice for 10 minutes. The cells were then scraped from the dish,
transferred to a sterile 1.7 mL Eppendorf tube, and placed on ice for an additional 30
minutes to allow cells to lyse. The cell suspension was centrifuged for 10 minutes at
10,000 rpm and the soluble protein fraction was transferred to a separate tube. Protein
concentration was determined using the Bradford method by mixing 1 µL of the whole
cell extract with 799 µL sterile distilled water (SDW) and 200 µL Bradford reagent (BioRad Inc.). The mixtures were transferred to a 96-well plate (200 µL/well) and
absorbance at 595 nm was determined in duplicate on a spectrophotometer. A standard
curve was generated using bovine serum albumin (BSA) protein ranging from 0.5 µg/µL
to 10 µg/µL. The sample absorbance values were regressed against the standard curve to
determine protein concentration. An amount of 200 µg of protein was mixed with an
equal volume of 2X SDS loading dye (60 mM Tris, pH 7.6, 2% SDS, 10% glycerol, 5%
β-ME, and 1% bromophenol blue), and boiled at 100oC for 5 minutes prior to loading on
a sodium dodecyl sulfate 10% polyacrylamide gel. The gel was run at 150 constant volts
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for approximately 5 hours in 1X SDS running buffer (25 mM Tris pH 8.3, 250 mM
glycine, 0.1% SDS). The proteins were transferred onto a polyvinylidene difluoride
membrane (Millipore) in a transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol,
pH 8.3) using a Transblot system (Bio-Rad) overnight at 50 constant volts. The
membrane was incubated in 50 mL blocking buffer (1X Tris Buffered Saline (TBS), 5%
non-fat dry milk, 0.2% Tween-20) for 1 hour on a rotary platform shaker at room
temperature. Immunoblotting was performed at room temperature using the appropriate
primary antibodies at 1:500-1:10,000 dilution in 1X TBS containing 5% non-fat dry milk
for a least 1 hour on a rocker. The blot was then washed 3 times for 15 minutes each in
TTBS (1X TBS, 0.1% Tween-20) on a platform shaker. The appropriate secondary
antibody, either goat anti-mouse or goat anti-rabbit HRP-conjugated (Promega), was
diluted 1:5,000-1:10,000 in 1X TBS containing 5% non-fat dry milk and added to the blot
for at least 1 hour on a rocker. The membrane was washed 3 times in TTBS as
previously described, and then exposed to Super Signal chemiluminescent reagent
(Pierce) for 3-4 minutes, and protein was visualized on a FUJI FILM LAS 3000 image
reader. The antibodies were removed from the membrane by incubating the blot in
Western strip buffer (25 mM glycine, 1% SDS, pH 2.0) for 30 minutes at room
temperature on a platform shaker. The membrane was then immunoblotted with another
primary antibody according to the method indicated above.
H. Luciferase Repoter Assay
MCF7 cells were seeded at 100,000 cells per well in a 24-well plate, and were
reverse transfected with 100 nM siRNA at the time of seeding in duplicate per siRNA
target. After 24 hour incubation at 37oC, the cells were co-transfected with siRNA, the
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p53 Luciferase reporter plasmid, pG13Luc, and the Renilla luciferase plasmid, RLuc.
The pG13Luc plasmid contains 13 copies of the p53 consensus sequence, 5’PuPuPuC(A/T)(T/A)GPyPyPy (El-Deiry et. al., 1992) in its promoter and the RLuc
plasmid was used as a transfection efficiency control. The amount of luciferase protein
expressed in the sample correlates with the level of p53 transcriptional activity. Twentyfour hours post co-transfection, the cells were lysed directly in the plate by adding 75 µL
Passive Lysis buffer (Promega) per well and placing the plate on a rocker for 30 minutes.
The lysates were transferred to a sterile 1.7 mL Eppendorf tubes and p53 transactivation
was determined using the Dual-Luciferase Assay (Promega) per the manufacturer’s
protocol. Briefly, a 5 µL aliquot of the extract was thoroughly mixed in 50 µL LAS
reagent (Promega), and place immediately in the luminometer. The value was recorded,
and then 50 µL of Stop & Glo reagent (Promega) was added to the tube, mixed and
placed in the luminometer to determine RLuc value. Each sample was analyzed in
duplicate and the ratio of the pG13Luc value to RLuc value was determined. Cells
treated with 0.5 µg/mL doxorubicin for 24 hours were used as a positive control for p53
transcriptional activity, while cells transfected with sip53 served as a negative control for
the assay. Non-transfected cells were used to measure background activity. The mean
pG13Luc/RLuc ratio was graphed and error bars represent the standard deviation derived
from relative luciferase values from 4-6 samples per RNAi treatment condition.
I. Colony Formation Assay
Cells were reverse transfected with siRNA and 24 hours later transfected a second
time with siRNA as previously described. Then 24 hours following the second
transfection, the cells were trypsinized in 1 mL of 0.25% Trypsin/EDTA (Gibco) per 6-
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cm dish. Once the cells detached from the dish, they were diluted in complete media,
counted on a hemocytometer and reseeded at 500 cells per well in 6-well plates in
antibiotic free DMEM containing 10% BGS. The cells were allowed to grow and form
colonies for ten days during which time the media was changed every three days. After
ten days, the colonies were fixed and stained for 20 minutes with 1% crystal violet in
70% methanol. The excess stain was removed by washing the plates with water until the
water was clear. The plates were allowed to air dry, and the colonies were counted, or
quantified on the FUJI FILM LAS 3000 image reader.
J. Cell Proliferation Assay
Cells were trypsinized 24 hours after the second siRNA transfection, counted on
a hemocytometer, and seeded at 2,000 cells per well in quadruplicate. The seeding
efficiency of the various siRNA transfected cells was determined the following day after
seeding (Day 0) by removing the culture media, fixing and staining the attached cells
with 1% crystal violet in 70% methanol, washing off the excess stain, extracting the
bound stain with 100 µL of 10% acetic acid per well, and determining absorbance at 590
nm (A590) on a spectrophotometer. The seeding efficiencies appeared to be very similar
among all the transfected cells. Cell proliferation was determined on Days 2, 4, 6, and 8
relative to Day 0 by fixing and staining the cells as indicated above. The A590 value
obtained on Day 0 was used for normalization. Growth curves were generated by plotting
mean A590 vs. Day, and error bars represent the standard deviation of 4 samples per time
point per siRNA transfection condition.
To determine cell viability post treatment with chemotherapeutic agents, cells
were seeded at 20,000 cells/well in 96-well plates in triplicate. Cell viability was assessed
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by using either CellQuanti-Blue™ Reagent (BioAssay Systems) according to
manufacturer’s protocol or by staining the cells with 1% crystal violet and quantifying
the stain by reading absorbance at 590 nm as previously described. Cells were treated
with various doses of the chemotherapy drug on Day 0, and incubated at 37oC for 24 or
48 hours. After drug treatment, the media was removed, cells were washed once in
media to remove drug, and 150 µL of fresh media containing 10% CellQuanti-Blue™
Reagent was added to each well. The plates were returned to the incubator and
approximately two hours later, 100 µL of media per well was transferred to a black 96well plate (Costar) and fluorescence intensity (FI) was determined at 530 nm excitation,
590 nm emission on a Safire2 Fluorescence plate reader (TECAN). The cell viability (%)
was calculated by the following equation: % cell viability = 100 x (FIcmpd/FIcon) where
FIcmpd is the FI in the presence of drug and FIcon is the average FI in the absence of the
drug. The average % cell viability is plotted for each dose and error bars represent the
standard deviation of 3 samples.
K. Flow Cytometry
Cells were trypsinized in 1 mL of 0.25%Trypsin/EDTA per 6-cm dish 18-24
hours after the last siRNA transfection. Trypsinized cells were collected in a 15 mL
sterile centrifuge tube, centrifuged at 1200 rpm for 5 minutes to pellet the cells and then
the cells were washed once in 5 mL DPBS. The cells were pelleted by centrifugation as
above, the DPBS was decanted and the cells were resuspended in the small volume
remaining by flicking the tube. While vortexing, 2 mL of 70% ethanol was added to each
tube in a drop-wise manner, and the tubes were stored at -20oC until ready to do flow
analysis. The tubes were centrifuged at 1200 rpm for 5 minutes to pellet the cells, the
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cells were washed once in DPBS, centrifuged again, and the cells were suspended in the
remaining liquid. The cells were treated with 500 µL of RNAse A (1 mg/mL) in DPBS
for 20 minutes at 37oC, and then stained with 50 µg/mL propidium iodide (Sigma, Inc.)
and placed on ice for 30 minutes. The cell suspensions were transferred to flow tubes
and covered with foil to protect from light. Cell cycle distribution was determined by
flow cytometry (channel FL2) on a FACSCAN (Becton Dickinson). The experiment was
repeated three times and the percentage of cells in G1, S, and G2/M phases were obtained
using ModFit LT 3.0 software (Verity Software House, Inc.). The ratio of G1 to S phase
cells is indicated in the bar graph.
L. Nuclear and Cytoplasmic Protein Extraction
MCF7 cells were triple transfected and 24 hours following the last siRNA
transfection, the cells were refed with fresh media containing 20 µM MG132 for 4 hours
to inhibit proteosomal degradation of HdmX, Hdm2 and p53 protein. After 4 hours, the
cells were washed once with DPBS, scraped from the dish, and transferred to a sterile
tube for centrifugation. The cell pellet was resuspended in 200 µL cold CER I reagent
(Pierce) by vigorously vortexing, and then the cells were placed on ice for 10 minutes.
Next, 15 µL CER II reagent (Pierce) was added to each tube and the cytoplasmic extract
fraction was prepared. The remaining cell pellet was resuspended in 90 µL cold NER
reagent (Pierce) and the nuclear extract fraction was isolated per manufacturer’s protocol.
Protein concentration was determined by Bradford method and extracts were stored at
-80oC. 150 µg of protein was loaded per lane on a SDS 10% polyacrylamide gel and
Western blot analysis was performed as previously described.
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III. RESULTS
A. Selection of hdmX target sequence and siRNA transfection optimization.
To examine the effects of HdmX knockdown on tumor cells with wild-type p53
and over-expressed HdmX, several human tumor cell lines were utilized. The baseline
levels of hdmX, hdm2, and p53 gene expression were determined for each cell line by
quantitative real time-PCR (RT-PCR) (Figure 9). Likewise, HdmX protein expression
level relative to normal melanocytes were previously reported (Ramos et al., 2001) for
some of the cell lines and determined by Western blot relative to MCF7 and H1299 cells
for the others. Table 3 summarizes the relative endogenous HdmX expression level and
the p53 status of all the cell lines utilized in this study.
Initial experiments were conducted using a pool of four siRNAs obtained from
Dharmacon (SMARTpool™) which target the hdmX transcript, but have different target
sequences. The pooled siRNAs successfully decreased hdmX gene expression by
approximately 50% relative to a pool of non-targeting siRNAs (siCon) in MCF7 cells 24
hours following a single siRNA transfection using Oligofectamine (Figure 10A).
Although the knockdown of HdmX was modest, the p53 target gene, p21, was induced
both transcriptionally and at the protein level (Figure 10B). The increase in p21 was also
observed in U2OS cells following loss of HdmX despite no significant effect on Hdm2 or
p53 levels (data not shown). These results correlate with previous reports that showed
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Figure 9. RT-PCR analysis of hdmX, hdm2, and p53 gene expression
in various tumor cell lines. The endogenous levels of hdmX and hdm2
were determined relative to the levels in H1299 cells. The endogenous
levels of p53 were determined relative to the levels in U2OS cells since the
H1299 cells are p53 null.

All samples were normalized to GAPDH

(internal control).
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Cell line

p53 status

HdmX level

MCF7

wild-type

high

U2OS

wild-type

high

HCT116-p53+/+

wild-type

high

HCT116-p53-/-

null

high

wild-type

normal

H1299

null

low

Saos-2

null

low

IMR90

wild-type

normal

U87

Table 3. HdmX level and p53 status of various cell lines. HdmX
protein levels were determined via Western blot relative to normal nontumor cells, whereby high indicating at least a 2 fold increase and low
representing half the level of HdmX (Ramos et al., 2001). Β-Actin was
used as a loading control.
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Figure 10. Loss of HdmX induces p21 expression. (A) RT-PCR analysis of
hdmX, p21, and hdm2 gene expression in MCF7 cells 24 hours post siRNA
transfection. The fold change relative to siCon transfected cells is shown. (B)
Western blot analysis (Top panel) and quantification (Bottom panel) of p21 protein
levels in MCF7 cells 48 hours following siRNA transfection. Loss of HdmX leads
to a 2.5 fold increase in p21 protein expression. Actin was used as a loading
control.
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partial HdmX knockdown induced p21 without a detectable increase in Hdm2 or p53
(Danovi et al., 2004).
To identify the most effective target sequence for silencing hdmX, each siRNA
was individually transfected into U87 cells. The location of the four different target
sequences on the hdmX gene is illustrated in Figure 11A. Twenty four hours following
transfection, total RNA was isolated and hdmX and p21 gene expression was determined
by TaqMan-based RT-PCR. Two of the siRNA target sequences (#1 and #4) decreased
hdmX transcript by 44% and 46%, respectively, while the other two siRNAs were less
effective (Figure 11B). The induction of p21 generally correlated well with the level of
HdmX knockdown. Thus, siRNA sequence #1 (siHdmX1) and sequence #4 (siHdmX4)
targeting hdmX were used throughout this study. Similar experiments were performed to
identify the most effective target sequences for knockdown of hdm2 in MCF7 cells. The
siRNA sequence #6 (siHdm2(6)) was the best followed by sequence #9 (siHdm2(9)).
To properly assess the effect of HdmX knockdown on p53 activity in tumor cells
with wild-type p53 by RNAi, it was necessary to improve upon the ~45% reduction seen
with the single siRNAs following a single transfection. In order to optimize the siRNA
transfection efficiency, a cytotoxic RNA-based reagent for optimizing siRNA delivery
into cultured cells (siTOX; Dharmacon), was employed. MCF7 cells were transfected
once with either 50 nM or 100 nM siTOX or siCon using Lipofectamine 2000 or
Oligofectamine, and 72 hours later cell viability was determined by CellQuanti-Blue™
reagent (Figure 12). There was 38-47% cell viability detected in the siTOX transfected
cells compared to mock transfected (lipid only) control cells, suggesting that
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Figure 11. Selection of target sequence for silencing HdmX expression.
(A) Schematic representation of the HdmX gene showing exons 1-12 and the
location of the four siRNA target sequences examined (shRNAs #1-4). The
numbers in the parentheses are the percent knockdown in U87 cells relative to
mock (lipid only) transfected control (B) RT-PCR analysis of hdmX and p21
gene expression in U87 cells 24 hours following a single siRNA transfection.
Relative quantity (RQ) represents the fold change relative to mock.
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Figure 12. MCF7 cell viability 72 hours post siTOX transfection.
The % cell viability relative to mock transfected cells was determined by
CellQuanti-Blue™ reagent. A single siTOX transfection resulted in about 40%
cell viability whether Lipofectamine 2000 and Oligofectamine was used.
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approximately 55-60% of the cells were transfected with the siRNA. This result
correlated well with the ~ 50% knockdown of hdmX observed following a single
siHdmX transfection. The cells transfected with siCon retained 100% cell viability
relative to mock indicating that siRNA transfection does not lead to cytotoxicity. There
was no significant difference in transfection efficiency observed between Lipofectamine
2000 and Oligofectamine, or 50 nM and 100 nM siTOX.
Multiple siRNA transfections were utilized to increase the siRNA delivery into
the cells. Increasing the concentration of siRNA molecules per transfection was not a
feasible option due to increases in off-target effects when greater than 100 nM of siRNA
was used. MCF7 cells were transfected with 100 nM siTOX on three consecutive days
and cell viability was assessed at 48 and 72 hours later. By 48 hours, cell viability had
decrease to 40% and by 72 hours, less than 10% of the cells were remaining on the plate,
indicating that ~90% of the cells had been transfected with siTOX. The siCon triple
transfected cells retained 93-98% cell viability relative to non-transfected control cells.
Triple transfection with siHdmX effectively decreased hdmX gene expression by 85-90%
in MCF7 cells (Figure 13A) and HdmX protein was almost completely eliminated as
determined by Western blot (Figure 13B). The loss of HdmX led to an increase in both
p21 and hdm2 gene expression, but not p53 gene expression. Using the reverse
transfection method (see Materials & Methods) was equally as effective as triple
transfection at decreasing hdmX levels in MCF7 cells, so it was also used throughout this
study. However, the reverse transfection method was recommended for the MCF7 cells
only (Invitrogen technical bulletin), so triple transfection was used for the other cell lines.
Although the transfection efficiency is very good using the triple transfection and reverse
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Figure 13.

HdmX and Hdm2 knockdown following triple siRNA

transfections. (A) RT-PCR analysis of hdmX, hdm2, p21, and p53 in MCF7 cells
24 hours after the third siRNA transfection. (B) Western blot analysis showing
loss of HdmX and Hdm2 protein by siHdmX and siHdm2 transfections,
respectively. Cells treated with 0.5 µg/mL doxorubicin for 24 hours served as a
positive control of p53 activation.
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HdmX

Figure 14.

Duration of HdmX and Hdm2 knockdown following triple

transfection in MCF7 cells.

RT-PCR analysis of hdmX and hdm2 gene

expression shows that hdmX is reduced for three days post transfection (left
panel) and hdm2 is decreased for up to five days post transfection (right panel).
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transfection methods, the knockdown was only a transient effect. After triple
transfection, hdmX gene expression was reduced for three days and hdm2 expression was
reduced for five days (Figure 14) following siHdmX and siHdm2, respectively, in MCF7
cells. In order to achieve a stable long term knockdown, the siHdmX1 sequence was
cloned into a lentivirus vector expressing a short-hairpin RNA that targets hdmX
(shHdmX), and stable cell lines were established.
B. Non-specific induction of p53 target genes by Lentivirus-delivered shRNA.
U2OS and MCF7 cell lines stably expressing shHdmX or the control short-hairpin
RNAs targeting Lamin (shLamin) or LacZ (shLac) were established. The Lentivirus
delivered shHdmX was effective at reducing hdmX transcript in U2OS cells (Figure 15
A), but not as effective in MCF7 cells (Figure 15B), although HdmX protein levels were
reduced by at least 50% in MCF7 cells stably expressing shHdmX (Figure 15C). The
control cells expressing shLamin and shLac had no effect on HdmX expression as
expected. To determine if silencing HdmX in tumor cells which retain wild-type p53 will
activate p53 and induce p53 target genes (i.e. p21, hdm2 and gadd45), quantitative RTPCR was performed on total RNA isolated from the stable cells. Unexpectedly the stably
infected shLamin and shLacZ control cells also expressed increased levels of several p53
target genes in both U2OS and MCF7 cells (Figure 15), suggesting that lentiviral shRNA
vectors may cause non-specific effects on untargeted gene expression. To examine the
possibility that these alterations in gene expression resulted from the viral infection rather
than the presence or processing of the shRNA vectors in the cell, U2OS cells were
infected with a tetracycline repressor (TR) expressing lentivirus. The induction of p21
and hdm2 was not observed after TR-lentiviral infection, suggesting that the increase in
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Figure 15. Non-specific induction of p53 target genes by Lentivirus-delivered
shRNA vectors.

(A) RT-PCR analysis of hdmX, hdm2, p21, and p53 gene

expression in U2OS cells stably infected with the indicated shRNA lentivirus.
(B) RT-PCR analysis of hdmX, hdm2, p21, and gadd45 gene expression in MCF7
cells stably infected with the indicated shRNA lentivirus. (C) Western blot of HdmX,
p21, and β-actin in MCF7 cells either uninfected, infected with shHdmX lentivirus
(shX) or infected with shLacZ lentivirus. HdmX was reduced by shX, but p21 was
induced by both shX and shLacZ.
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p53 target gene expression is specific to virus containing shRNA vectors rather than to a
general antiviral response by the cells. The p53 transcript level was not altered by
expression of shRNA vectors or viral infection as expected (Figures 15A & 15B). Lastly,
p21 protein levels where increased in all shRNA expressing cells relative to uninfected,
which correlates with the increased p21 gene expression that was observed (Figure 15C).
C. Induction of p21 is both p53-dependent and independent.
To determine if the non-specific untargeted induction of p21 mRNA by lentiviraldelivered shRNA vectors is p53 dependent, HCT116-p53+/+ and HCT116-p53-/- cells
were infected with lentiviral shRNA vectors targeting hdmX or LacZ. The cells were put
under selection for ten days and stable cells were harvested for protein. Western blot
analysis demonstrated an increase in both p53 and p21 protein levels in HCT116-p53+/+
cells following lentiviral infection (Figure 16A). This induction of p53 and p21 was not
specific to the cells with knocked down HdmX, but rather observed with both lentivirus
containing shRNAs. The HCT116 cells devoid of p53 (HCT116-p53-/-) also showed an
increase in p21 protein, but to a lesser degree than the HCT116 cells containing wild-type
p53, indicating both a p53-dependent and independent induction of p21 by shRNA
containing lentivirus (Figure 16A). The induction of p21 protein in HCT116-p53-/- cells
is the result of an increase in p21 transcripts, as the experiment was repeated and RNA
levels were quantified by RT-PCR. Again, increases in p21 mRNA levels were detected
in both p53-null and p53 wild-type cell lines expressing shRNAs (Figure 16B). To
confirm that the p53-independent induction of p21 is not specific to the HCT116-p53-/cells, the same experiment was performed in p53-null Saos-2 cells.
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Figure 16. Induction of p21 in HCT116 cells stably expressing shRNA
vectors. (A) Western blots of HdmX, Hdm2, p53 and p21 proteins in HCT116
cells either uninfected (Con) or infected and selected for stable expression of the
indicated shRNA vector. HdmX protein levels were reduced in both HCT116p53+/+ and HCT116-p53-/- cells stably infected with lentiviral-delivered shX,
but not in shLacZ stable cells as expected.

Unexpectedly, p53 and p21

expression were increased in both shX and shLacZ HCT116-p53+/+ cells.
Additionally, p21 and Hdm2 protein levels were also induced in a p53independent manner in HCT116-p53-/- cells stably infected with either shX or
shLacZ lentivirus. (B) RT-PCR analysis of hdmX and p21 gene expression from
HCT116 cells either uninfected (con) or infected with shX or shLacZ. Fold
change was normalized to HCT116-p53-/- Con cells.
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Figure 17.

Induction of p21 in p53-null Saos-2 cells expressing shRNA

vectors. (A) RT-PCR analysis of hdmX and p21 gene expression in Saos-2 cells
stably infected with shHdmX (shX) or shLacZ (shLac) expressing lentivirus.
Fold change is relative to expression in uninfected cells.

Results show an

induction of p21 in both shRNA expressing cells and knockdown of hdmX
mRNA only in the shX expressing cells. (B) Western blot showing induction of
p21 protein in both shRNA-expressing stable cell lines. Since the levels of HdmX
protein are low in Saos-2 cells, it is difficult to detect the knock-down of HdmX
protein by Western blot.

60

Saos-2
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Indeed, the non-specific induction of p21 gene and protein expression was observed in
Saos-2 cells as well post shHdmX and shlacZ lentiviral infections relative to uninfected
cells (Figure 17). Overall, these results suggest that the off-target effect seen with the
shRNA vectors is predominantly p53-independent. Conversely, transient transfection
with siCon did not induce the off-target expression of p21 as seen with the shRNA
vectors (Figure 9). The induction of p53 target genes suggests that p53 is being activated
by shRNA in a non-specific untargeted manner in tumor cells harboring wild-type p53.
To examine the transcriptional activity of p53, cells were co-transfected with a p53
luciferase reporter plasmid (pG13Luc) containing thirteen p53 consensus binding sites in
its promoter, and with a transfection control plasmid (RLuc). HCT116-p53+/+ cells
stably infected with lentiviral-delivered shRNA targeting hdmX and LacZ had increased
levels of activated p53 relative to uninfected cells (Figure 18) The HCT116-p53-/- cells
stably expressing shHdmX and shLacZ were co-transfected with pG13Luc and RLuc, and
used as a negative control. Thus, it appears that the presence and/or processing of the
lentiviral delivered shRNA vectors are causing a non-specific cellular stress leading to a
modest increase in p53 transactivation and an induction of untargeted p53 response
genes.
D. Investigation of shRNA lentivirus mediated interferon response.
Some shRNA vectors have been reported to activate a non-specific antiviral response
against dsRNA molecules in cells (Bridge et al., 2003). To investigate whether or not the
lentiviral shRNA vectors are triggering an interferon response (IFN) in the MCF7,
HCT116, and U2OS cells, the expression of OAS1 (2’5’-oligoadenylate synthetase) a
classic IFN target gene that is induced by >50-fold upon activation of the IFN response
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(Bridge et al., 2003) was measured. Quantitative RT-PCR analysis of OAS1 expression
in shHdmX and shLacZ lentiviral infected MCF7 cells showed a 29 and 16 fold
induction, respectively, relative to uninfected control (con) cells (Figure 19A), suggesting
a possible activation of the interferon response. However, no effect on OAS1 gene
expression was observed in the HCT116-p53-/- cells following infection of lentiviraldelivered shRNA vectors, and HCT116-p53+/+ cells had a less than 4-fold induction
(Figure 19B). Furthermore, stably infected U2OS cells showed little or no induction of
OAS1 gene expression (Figure 19C), suggesting that p21 induction is not the result of a
classic anti-viral interferon response. Similar results were observed with IFIT1
(interferon-induced protein with tetratri-copeptide repeats 1) expression, another
interferon response gene, in HCT116 cells (Figure 20A) and MCF7 cells (Figure 20B).
Since p21 was induced in a non-specific untargeted manner in all of the shRNA
expressing stable cell lines tested, these results indicate that an interferon response is not
necessary to elicit induction of p21 by lentivirus delivered shRNA.
To examine if IFN can trigger an increase in p21 gene expression in tumor cells,
MCF7 and HCT116 cells were treated with 50 ng/mL IFN-γ for 24 hours. Quantitative
RT-PCR analysis clearly demonstrated that IFN treatment does not induce p21 in MCF7
or HCT116 cells, while significantly inducing the IFN target gene, OAS1 by >18 fold in
MCF7 cells, 80-fold in HCT116-p53+/+ cells and 45-fold in HCT116-p53/- cells
(Figures 20A & 20C). Finally, western blots of MCF7 cells treated with IFN or infected
with lentiviral delivered shRNA-vectors confirm that p21 protein induction occurs upon
shRNA expression but not with interferon treatment (Figure 20B).

63

Figure 18. Lentivirus-delivered shRNAs activate p53 in HCT116-p53+/+.
A p53 luciferase reporter plasmid (pG13Luc) was employed to measure p53
transcriptional activity and a renilla luciferase plasmid (RLuc) was used to
normalize transfection efficiency. Both shHdmX and shLacZ lentiviral infected
HCT116-p53+/+ cells showed increased p53 transactivation relative to uninfected
cells (Con). HCT116-p53-/- cells showed background levels only. Bars represent
the mean pG13Luc/RLuc ratio and error bars represent standard deviation of four
samples.
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Figure 19. RT-PCR analysis of OAS1 and p21 gene expression. (A) OAS1
gene expression is highly induced in MCF7 cells stably expressing shRNA
relative to uninfected cells (con). (B) OAS1 mRNA levels were not altered in
HCT116-p53-/- cells, while HCT116-p53+/+ cells infected with lentivirus
containing shRNAs showed <4 fold increase. (C) OAS1 levels were not
changed in U2OS cells, however, p21 gene expression was consistently
increased by 2-3 fold in all cell lines infected with shRNA expressing
lentivirus.
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Figure 20. RT-PCR analysis of IFIT1 gene expression. (A) IFIT1 gene
expression in HCT116 cells stably expressing shHdmX or shLacZ.

IFIT1

transcripts were induced in HCT116-p53+/+ cells, but not p53 null HCT116 cells
(B) IFIT1 gene expression in MCF7 cells either uninfected (con), stably infected
with shX or shLacZ lentivirus, or treated with 50 ng/mL Recombinant human
Interferon-gamma (IFN).

IFIT1 expression is induced by both lentiviral-

delivered shRNA vectors and by IFN treatment.
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Figure 21. p21 is not induced by IFN in MCF7 cells or HCT116 cells.
(A) RT-PCR results from MCF7 cells treated with 50 ng/mL IFN for 24 hours.
While OAS1 gene expression increased 18-fold, no change in p21 gene
expression relative to untreated, was observed. (B) Western blot analysis of p21
protein levels in MCF7 cells treated with interferon-gamma (IFN+) or infected
with lentivirus expressing shHdmX or shLacZ showed p21 protein was induced
in the shRNA-expressing MCF7 cells only. Beta-actin was used as a loading
control. (C) RT-PCR results from HCT116 cells treated with 50 ng/mL IFN for
24 hours. OAS1 gene expression was significantly induced in both wild-type p53
and p53 null HCT116 cells, while p21 gene expression was not altered.
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Since lentiviral delivered shRNA has the advantage of stable long term silencing
over transient siRNA transfections, viral shRNA delivery systems have gained wide use
in creating stable knockdown cell lines. To investigate the role of HdmX deregulation of
p53 function in tumor cells, we designed lentiviral-delivered shRNA vectors which were
effective in knocking down HdmX expression and inducing p53 target genes. However,
it was quickly determined that expression of control shRNAs (shLamin, shLacZ) also
triggered activation of p21 and gadd45. The non-specific induction of these p53 target
genes was not sequence-dependent since every shRNA control used elicited a similar
response, nor was it due to the drug selection since elevated p21 levels were observed
even after removal of selection. Additionally, since Lentivirus expressing the
Tetracycline repressor did not induce p21 transcripts, the possibility that the off-target
p21 induction was due to a general anti-viral response by the cells was excluded. Since
p21 expression was also increased in p53 null cell lines expressing shRNA, it implied
that this effect was both p53-dependent and independent. For these reasons, the
lentivirus shRNA system could not be used in our studies to identify alterations in gene
expression in tumor cells following the loss of HdmX.
E. Alterations in gene expression following the loss of HdmX
MCF7 cells which possess wild-type p53 and elevated levels of both HdmX and
Hdm2 were used to elucidate alterations in gene expression following the loss of HdmX
or Hdm2. Triple siRNA transfections were performed to knockdown approximately 90%
of the HdmX or Hdm2 in the cells and an Affymetrix GeneChip® experiment was
conducted. Each experimental siRNA was transfected into three separate wells and 24
hours after the last transfection, total RNA was isolated individually from each well for
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hybridization onto three separate GeneChips. The expression levels of select genes were
monitored to confirm that the GeneChip experiment had run as expected and that the
knockdown was detected (Figure 22). The levels of knockdown of HdmX, Hdm2, and/or
p53 detected by the GeneChips are illustrated in Figure 22.
GeneSpring software was employed to generate lists of genes that were induced
by at least two fold following knockdown of HdmX or Hdm2 relative to siControl.
Additionally, lists of genes that were suppressed by a least 50% after loss of HdmX or
Hdm2 relative to siControl were created using GeneSpring. The total number of genes
altered in MCF7 cells after triple transfection with the indicated siRNAs are summarized
in Table 3. As shown in the table, two different target sequences were used to
knockdown HdmX (#1 and #4) and two target sequences were used for Hdm2
knockdown (#6 and #9). Using GeneSpring, we identified the number of genes that are
common to both lists (i.e. siHdmX1 + siHdmX4). Focusing only on those genes that
were present in the combined list decreased the probability that the gene alterations
represented off-target effects from the siRNA for either hdmX or hdm2. The knockdown
of HdmX or Hdm2 in MCF7 cells led to the induction of several p53 regulated genes
(Table 4). Interestingly, the majority of these genes encoded proteins involved with p53mediated cell cycle arrest with only one pro-apoptotic gene showing a significant
increase (Fas, Table 4). Several of the other p53 target genes induced, whose functions
are not as well known, appear to play a role in growth inhibition, cell adhesion, and
differentiation. While the loss of either HdmX or Hdm2 did not appear to activate p53
pro-apoptotic genes, the removal of p53 from MCF7 cells by siRNA targeting p53
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mock
siCon
siHdm2(6)
siHdm2(9)
siHdmX(1)
siHdmX(1)+sip53
siHdmX(4)
sip53
BAX p21

----GADD45--A
B

Hdm2

HdmX

p53

Figure 22. Expression levels of select genes following siRNA transfection. The
color scheme represents the average signal for the three replicates per condition. Red
represents genes which are induced, while green represents genes which are
suppressed and yellow are genes which are not altered 24 hours following triple
siRNA transfection in MCF7 cells.
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Table 4. Number of genes altered relative to siControl. Number of genes
induced and suppressed by the indicated siRNA transfections in MCF7 cells.
siHdmX+siHdmX4 shows the number of common genes between the siHdmX1
list and the siHdmX4 list.
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Cell Cycle

Apoptosis

DNA Repair

p21

Fas

p48

GADD 45

BAX

p53R2

BTG2

IGF-BP3

PCNA

Cyclin G

NOXA

14-3-3σ

PIGs

Reprimo

PUMA

B99

p53AIP

Growth
Inhibition/
Unknown
ACTA2
WIG1

Other/
Unknown
Hdm2
RAI

PERP

Table 5. Functional groups of selected p53 target genes. The genes in red indicate
genes that were induced by loss of HdmX or Hdm2, and the genes in green represent
genes suppressed by loss of p53 in MCF7 cells. (Functional groupings adapted from
Levine and Feng, 2006; Jackson and Pereira-Smith, 2006)
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did lead to significant decreases in Fas, and two other pro-apoptotic genes, NOXA and
IGF-BP3. Taken together, our targeted analysis of known p53 regulated genes suggested
that the loss of either HdmX or Hdm2 led to a preferential induction of p53 regulated
genes involved in the inhibition of cell proliferation.
F. Validation of GeneChip data and induction of p53 target genes
In order to confirm the GeneChip results, quantitative RT-PCR using Taqman
primers targeting five known p53 target genes was performed. ACTA2, BTG2 and p21
are all p53 target genes that have been associated with growth inhibition (Boiko et al.,
2006; Comer et al., 1998) and cell cycle arrest (el-Deiry et al., 1993), while Hdm2 is a
negative regulator of p53 (Marine et al., 2006) and Noxa is a pro-apoptotic factor (Oda et
al., 2000a). All of these genes were induced following loss of hdmX and hdm2 in the
GeneChip experiment with the exception of NOXA. MCF7 cells were either mocktransfected (Con), transfected with siRNA that does not target any human gene (siCon) or
transfected with siRNA targeting HdmX or Hdm2 either alone or in combination. The
loss of HdmX or Hdm2 led to a significant increase in p21 gene expression relative to
siCon and the combination of HdmX and Hdm2 knockdown resulted in a greater,
synergistic increase in p21 (Figure 23A). The loss of HdmX also led to an increase in
hdm2 transcripts, which would be predicted if the removal of HdmX led to an increase in
p53 transactivation. BTG2 and ACTA2 gene expression relative to control cells were
induced following knockdown of HdmX and/or Hdm2, while no significant change in
gene expression was observed with Noxa (Figure 23B). Finally, when both HdmX and
Hdm2 were eliminated, the transcript levels of BTG2 and ACTA2 increased additively.
These results validate our GeneChip data that p53 target genes were induced upon HdmX
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and Hdm2 knockdown, and that cell cycle arrest and growth inhibition genes appeared
most sensitive to the loss of HdmX and/or Hdm2 in MCF7 cells.
To confirm that these increases in p53 target gene expression was the result of
p53 transactivation, p21 transcript levels were determined by RT-PCR in two different
p53 null cell lines. HCT116 cells with wild-type p53 (HCT116-p53+/+) and HCT116
cells lacking p53 (HCT116-p53-/-) were transfected with either siCon, siHdmX, siHdm2,
or the combination of siRNAs targeting HdmX and Hdm2. p21 gene expression was
induced in the HCT116-p53+/+ cells after loss of HdmX or Hdm2 (Figure 24A), but not
in the HCT116-p53-/- cells relative to control cells (Figure 24B). Furthermore, in the p53
null H1299 cells, neither p21 nor BTG2 expression were significantly altered following
knockdown of HdmX or Hdm2 (Figure 25). Taken together, these results confirm that
the loss of HdmX and Hdm2 leads to an increase in p53-dependent activation of cell
cycle arrest genes.
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A

B

Figure 23. RT-PCR validation of siRNA knockdown in MCF7 cells.
(A) The hdmX, hdm2, and p21 mRNA expression relative to siCon (nontargeting siRNA) is shown. The p21 transcript is induced following loss of
HdmX or Hdm2, and synergistically induced following loss of both HdmX and
Hdm2.

(B) BTG2, ACTA2, and NOXA mRNA expression relative to

untransfected control (Con). The p53 target genes, BTG2 and ACTA2, are
induced by loss of HdmX and/or Hdm2, while the expression of the proapoptotic gene, NOXA, is not altered.
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A

HCT116-p53+/+

B

HCT116-p53-/-

Figure 24. Loss of HdmX and Hdm2 induce p21 in a p53-dependent manner.
Knockdown of HdmX, Hdm2 or the combination of Hdms in HCT116-p53+/+
cells (A) or HCT116-p53-/- cells (B). p21 transcript levels are significantly
induced in HCT116 cells harboring wild-type p53 following knockdown of HdmX
and/or Hdm2, but are not induced in p53-null HCT116 cells.
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Figure 25. Loss of HdmX does not induce p21 or BTG2 in p53-null H1299
cells. RT-PCR analysis of hdmX, hdm2, p21, and btg2 gene expression in H1299
cells 24 hours post siRNA infection. The p53 target genes; hdm2, p21, and btg2
were not induced following partial knockdown of HdmX and/or Hdm2.
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G. Loss of HdmX increases p53 transactivation
To examine how the knockdown of HdmX, Hdm2 or p53 in MCF7 cells affected
p53 transcriptional activity, a p53 luciferase reporter gene possessing 13 copies of the
p53 consensus DNA binding site (pG13-Luc) was employed. As a positive control,
MCF7 cells were transfected with the p53-reporter and then the cells were treated with
0.5 µg/mL doxorubicin (Dox) to trigger DNA damage and induce p53 transactivation
(Kurz et al, 2004). As expected, the loss of HdmX or Hdm2 led to an increase in p53
transactivation which was completely eliminated by the knockdown of p53 (Figure 26,
top panel). Interestingly, loss of HdmX resulted in greater p53 activation than the loss of
Hdm2 and the combined knockdown was similar to that seen with siHdmX alone. The
level of p53 transactivation following doxorubicin treatment was significantly greater
than that seen when HdmX and/or Hdm2 were eliminated (Figure 26, top panel).
Western blot analysis of HdmX, Hdm2, p53, p21, and β-actin was performed to confirm
knockdown of the indicated proteins and to evaluate protein levels following gene
silencing. The p21 protein levels were increased after loss of HdmX and/or Hdm2, and
after doxorubicin treatment as expected (Figure 26, bottom panel). However, p53 protein
levels were not significantly altered by HdmX and/or Hdm2 knockdown, while p53
stability was greatly increased following DNA damage triggered by doxorubicin. Since
the transfection of siRNAs targeting HdmX or Hdm2 increased p53 transactivation and
induced p53 response genes, but appeared to have little effect on p53 stability, we
investigated the phosphorylation of p53 following loss of HdmX and/or Hdm2.
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Figure 26. p53 transactivation is increased in MCF7 cells following loss of
HdmX or Hdm2. MCF7 cells were transiently co-transfected with a p53 reporter
(pG13Luc) and a CMV-driven renilla luciferase (RLuc) expression vector with the
second siRNA transfection or with 0.5 µg/mL doxorubicin for 24 hours. Top
panel: Dual luciferase activity reported as the ratio of pG13Luc/RLuc. The
transcriptional activity of p53 is increased following Dox treatment and
knockdown of Hdms, and eliminated in cells transfected with siRNA targeting
p53. Bottom panel: Western blot analysis of indicated proteins from the various
siRNA or Dox treated cells.

p21 protein levels are increased following

knockdown of HdmX and/or Hdm2 and with dox treatment as expected.
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H. Loss of HdmX does not trigger p53 phosphorylation.
Post-translational modifications of p53 are induced by genotoxic stress in order to
facilitate p53 stabilization and activation (Unger et al., 1999). One such modification is
phosphorylation, which occurs at multiple sites including serines 6, 9, 15, 20, 37, 46, and
392. The phosphorylation of p53 at serines 6, 15, 20, 46, and 392 was assessed in MCF7
cells following knockdown of HdmX and/or Hdm2 by Western blot using phosphorspecific p53 antibodies (Cell Signaling Technology, Inc.). Cells treated with 0.5 µg/mL
doxorubicin showed a significant induction of p53 and p53 phosphorylation at serines 15,
20, 46, and 392. A slight increase in p53 protein level was observed when both HdmX
and Hdm2 were eliminated, but no significant p53 phosphorylation was detected using
phospho-specific antibodies targeting serines 6, 15, 20, 46 or 392 (Figure 27). Based on
these results, we conclude that the loss of HdmX and Hdm2 does not trigger a cellular
stress that leads to any significant phosphorylation of p53.
I. Inhibition of cell growth after HdmX knockdown.
Since the loss of HdmX or Hdm2 appeared to preferentially activate p53 target
genes encoding proteins associated with cell cycle arrest and growth inhibition, we
examined how cell proliferation was impacted by HdmX knockdown. MCF7 cells were
plated at low density in 6-well plates following siRNA transfection, and cells were
allowed to grow for an additional ten days. Colony formation was assessed after fixing
and staining the cells. Transfection with siCon or siRNA targeting p53 (sip53) showed
only minimal changes in colony formation relative to non-transfected control cells (Con),
while knockdown of either HdmX or Hdm2 alone or in combination led to significantly
fewer colonies (Figure 28).
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Figure 27. Neither HdmX nor Hdm2 knockdown triggers p53phosphorylation. Whole cell extracts from MCF7 cells were prepared 48 hours
after siRNA transfection. Cells treated with 0.5 µg/mL Doxorubicin were used
as a positive control.

Western blot analysis was performed with phospho-

specific antibodies for p53. Dox treatment triggered phosphorylation on serine
15, 20, 46, and 392, while the knockdown of HdmX or Hdm2 did not result in
any detectable p53 phosphorylation.
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Figure 28. Loss of HdmX and/or Hdm2 inhibits MCF7 colony formation.
Following siRNA transfections, MCF7 cells were seeded at 500 cells/well in 6well plates. The cells were allowed to grow for ten days then the colonies were
stained with crystal violet. Significantly fewer colonies were present following
knockdown of HdmX (siHdmX) or Hdm2 (siHdm2), with the fewest number of
colonies present after removal of both Hdms (siX+si2). The cells transfected
with sip53 or a non-targeting control (siCon) showed minimal effects on colony
formation relative to non-transfected control (Con).
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Knockdown of both HdmX and Hdm2 led to the fewest colonies and the greatest growth
inhibition, which correlates well with the synergistic induction of the anti-proliferative
genes, p21, BTG2, and ACTA2.
In addition to colony formation, cell growth was assessed following loss of
HdmX and/or Hdm2 in MCF7 cells. Following triple siRNA transfection, MCF7 cells
were trypsinized and reseeded in quadruplicate at 2,000 cells/well in 96-well plates. The
cells were allowed to grow for 48 hours and the percent cell growth relative to
untransfected control was determined by staining the cells, solubilizing the stain and
reading absorbance at 590 nm. Transfection with siCon or sip53 had minimal effects on
cell growth, while siHdmX or siHdm2 alone inhibited growth by 30%, and the
combination of HdmX and Hdm2 knockdown led to a 50% reduction in cell growth
compared to an untransfected control (Figure 29). Growth curves were also generated
over an eight day period following siRNA transfection. Cells were seeded at 2,000
cells/well in quadruplicate in 96-well plates 24 hours post siRNA transfection, and then
2, 4, 6, and 8 days later the cells were stained, the stain was extracted, and the absorbance
was determined by spectro-photometer reading at 590 nm. The experiment was repeated
three separate times and each time cell growth was significantly inhibited by the loss of
HdmX and/or Hdm2, especially prior to day 6 (Figure 30). Once the transient
knockdown of HdmX and/or Hdm2 ended, the cells began to proliferate at a rate similar
to untransfected control cells. The siCon led to a slight delay in cell proliferation relative
to untransfected cells, while cells transfected with sip53 had a more significant, and
unexpected growth inhibition.
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Figure 29.

Loss of HdmX and Hdm2 inhibits cell proliferation.

Following transfections with the indicated siRNAs, MCF7 cells were seeded
at 2,000 cells/well in quadruplicate in 96-well plates.

The percent cell

growth relative to untransfected control (Con) was determined by staining
the cells and then quantifying the stain by reading absorbance at 590 nm.
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Figure 30. MCF7 cell proliferation is inhibited by knockdown of HdmX
and Hdm2. Following siRNA transfections, MCF7 cells were seeded at 2,000
cells/well in 96-well plates and allowed to grow for 2, 4, 6, and 8 days. The
absorbance at 590 nm (A590nm) was determined by staining the cells with
crystal violet and then quantifying the stain on a spectrophotometer after
extraction with 10% acetic acid.

The absorbance is proportional to cell

number.
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To assess how the decrease in cell proliferation induced by loss of HdmX and
Hdm2 affected cell cycle progression, the same experiments were repeated in MCF7 cells
and DNA content was analyzed by flow cytometry. The loss of either HdmX or Hdm2
led to an increase in G1 cells and a decrease in S phase cells (Figure 31A). MCF7 cells
transfected with siCon or sip53 maintained a cell cycle distribution similar to that of nontransfected cells (Con). The changes in cell cycle were quantified by plotting the G1/S
ratio for the various siRNA transfections. Both siHdmX and siHdm2 transfection
resulted in an approximately four fold increase in the G1/S ratio when compared to nontransfected cells (Con) or cells transfected with siCon or sip53 (Figure 31B). A similar
G1 cell cycle arrest was also observed in U2OS cells following HdmX knockdown by a
single siRNA transfection (Figure 32A). The difference in cell cycle distribution was
plotted as a ratio of the percentage of G1 cells to S phase cells. As seen with MCF7 cells,
loss of HdmX led to a significant increase in the G1/S ratio compared to mock
transfected and siCon transfected cells (Figure 32B).
J. Enhanced chemosensitivity after loss of HdmX
Since the knockdown of HdmX and Hdm2 appears to result in an antiproliferative effect rather than cell death, I examined whether the loss of HdmX or Hdm2
might sensitize the cells to chemotherapeutic agents. MCF7 cells were transfected with
the indicated siRNA, and 24 hours post transfection RT-PCR was performed to confirm
that the siRNA led to alterations in gene expression (Figure 33A). The cells were
trypsinized, counted and seeded at 20,000 cells/well in 96-well plates. Twenty-four
hours later (Day 0), cell viability was assessed to determine seeding efficiency and the
cells were treated with varying doses of doxorubicin (Dox) for 48 hours.
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B

Figure 31. HdmX knockdown triggers G1 cell cycle arrest in MCF7 cells.
MCF7 cells were stained with propidium iodide four hours after the second
siRNA transfection and cell cycle distribution was determined by flow
cytometry. (A) Histograms illustrating the cell cycle profiles after transfection
with the indicated siRNAs. (B) Ratio of the percentage of G1/S phase cells.
An increase in G1 and a decrease in S phase cells were observed following loss
of HdmX or Hdm2 indicating a G1 cell cycle arrest.
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Figure 32. Loss of HdmX triggers G1 cell cycle arrest in U2OS cells. U2OS
cells were stained with propidium iodide 24 hours after siRNA transfection and
DNA content was analyzed by flow cytometry.

(A) Histogram overlay

comparing cell cycle profiles from mock, siCon, and siHdmX transfected cells.
(B) Ratio of G1/S phase cells. Loss of HdmX resulted in an increase in G1 and a
decrease in S phase cells.
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Figure 33. Knockdown of HdmX enhances doxorubicin-induced cytotoxicity.
(A) RT-PCR analysis of hdmX, hdm2, p21 and p53 gene expression in the
indicated siRNA transfected MCF7 cells. The hdmX, hdm2, and p53 transcripts
were effectively knocked down by siRNA prior to drug treatment. (B) Percent cell
viability relative to untransfected untreated control cells. MCF7 cells were treated
with doxorubicin (0.25-1.0 µg/mL) for 48 hours and cell viability was determined
by absorbance at 590 nm. The loss of HdmX and/or Hdm2 showed an enhanced
cytotoxicity relative to control cells.
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Cell viability was determined by staining the cells, reading absorbance at 590 nm and
normalizing to Day 0. Knockdown of HdmX and/or Hdm2 increased the cytotoxicity of
doxorubicin, a topoisomerase II inhibitor, suggesting that the removal of p53 negative
regulators enhances the chemosensitivity of MCF7 cells to DNA damaging agents
(Figure 33B).
MCF7 cells were also treated with varying doses of AraC or cisplatin following
HdmX and/or Hdm2 siRNA transfection, and cell viability was assessed by the
fluorescent redox reagent, CellQuanti™-Blue. Western blot analysis of HdmX, Hdm2,
p53, and p21 was used to confirm successful knockdown by the indicated siRNA, and
activation of p21 (Figure 34A). Transfection with siRNAs targeting HdmX or Hdm2
increased the cytotoxicity of AraC, a DNA replication inhibitor (Figure 34B), similar to
doxorubicin. The removal of HdmX and Hdm2 enhanced the cytotoxicity of cisplatin, a
chemotherapy drug that cross links DNA to form adducts, however at doses of 20 µM or
greater this effect was seen in all siRNA transfected cells including siCon compared to
untransfected control cells (Figure 34C). As predicted by the alterations gene expression,
colony formation assays, and cell proliferation assays, the knockdown of both HdmX and
Hdm2 created the most cytotoxicity when combined with any of the agents tested.
K. Investigation of HdmX knockdown on Hdm2 and p53 localization and
stabilization.
Since HdmX can interact with both Hdm2 and p53, I examined how the removal
of HdmX would affect Hdm2 and p53 localization and stability. HdmX is predominantly
a cytoplasmic protein, where as Hdm2 is known to shuttle between the nucleus and the
cytoplasm. To assess Hdm2 and p53 localization in MCF7 cells following the loss of
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Figure 34. Knockdown of HdmX enhances Ara-C induced cytotoxicity.
(A) Western blot analysis of Hdm2, HdmX, p53 and p21 proteins in MCF7 cells
following the indicated siRNA transfections confirms knockdown. (B&C) Percent
cell viability relative to untransfected untreated control cells. MCF7 cells were
treated with AraC (0.1-0.5 µM) for 48 hours (B) or with cisplatin (5-20 µM) for 24
hours (C) and viability was determined by CellQuanti-Blue reagent. The loss of
HdmX and/or Hdm2 showed an enhanced cytotoxity relative to control cells.
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Figure 35.

Loss of HdmX or Hdm2 does not alter p53 localization.

Nuclear and cytoplasmic extracts were prepared from MCF7 cells following
HdmX or Hdm2 knockdown. The localization of p53, HdmX, or Hdm2 was
not altered by treatment with the indicated siRNA. The nuclear protein, Oct-1,
was used to monitor the purity of the protein extracts.
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HdmX, nuclear and cytoplasmic extracts were prepared and the proteins were resolved on
a SDS 10% polyacrylamide gel. Western blot analysis of HdmX, Hdm2, p53, Oct-1, and
β-actin revealed no significant changes in p53 or Hdm2 localization following HdmX
knockdown (Figure 35). The p53 protein is predominantly nuclear and its localization is
not changed by either removal of HdmX or Hdm2.
To assess Hdm2 and p53 localization in MCF7 cells following the loss of HdmX,
nuclear and cytoplasmic extracts were prepared and the proteins were resolved on a SDS
10% polyacrylamide gel. Western blot analysis of HdmX, Hdm2, p53, Oct-1, and β-actin
revealed no significant changes in p53 or Hdm2 localization following HdmX
knockdown (Figure 35). The p53 protein is predominantly nuclear and its localization is
not changed by either removal of HdmX or Hdm2. HdmX was predominantly
cytoplasmic as expected, and loss of Hdm2 did not appear to impact its localization.
Similarly, Hdm2 cellular distribution was not altered by the removal of HdmX, although
the total level of Hdm2 was increased following loss of HdmX likely resulting from
increased p53 transactivation since a proteasome inhibitor was present. These
observations were confirmed by measuring the density of each band on the Western blot
and determining the ratio of nuclear to cytoplasmic protein expression level. The ratios
were very similar among all the siRNA transfected cells. Oct-1, which is only found in
the nucleus, was used to monitor the purity of the nuclear and cytoplasmic protein
extraction. As expected, Oct-1 was only detected in the nuclear fraction (Figure 35).
Βeta-actin was included as a loading control since it is found in both the nuclear and
cytoplasmic fractions.

97

To examine Hdm2 and p53 stability following HdmX knockdown, MCF7 cells
were triple transfected with siRNA and 24 hours later the cells were treated with 20 µM
MG132 for four hours. The MG132 is a proteasome inhibitor which prevents
proteasomal degradation of p53, HdmX, and Hdm2. Since the loss of HdmX increased
hdm2 gene expression (Figures 23 and 33A), but an increase in Hdm2 protein by Western
blot was not detectable without a proteasome inhibitor, I investigated whether or not
Hdm2 stability was altered by the removal of HdmX. In the presence of MG132, an
increase in Hdm2 protein expression was detectable following the loss of HdmX;
suggesting that the increase in Hdm2 transcripts did led to increased protein levels
(Figure 36). Additional experiments were performed to assess if p53, Hdm2, or HdmX
half-life was altered after siRNA transfection in MCF7 cells. The cells were treated with
50 µg/mL cycloheximide (Sigma, Inc), a protein synthesis inhibitor, 24 hours after the
third siRNA transfection and protein was extracted 0, 1, 2, and 4 hours later. The loss of
Hdm2 stabilized p53 slightly as expected, whereas the loss of HdmX had little effect on
p53 stability (Figure 37A & B). However, the removal of HdmX, a binding partner of
Hdm2, appears to decrease Hdm2 stability possibly by leaving Hdm2 more vulnerable to
auto-ubiquitination and proteasomal degradation (Figure 37A & C). Likewise, removal
of Hdm2 appears to decrease HdmX stability relative to siCon transfected MCF7 cells
(Figure 37A). This is an unexpected result since upon DNA damage Hdm2 promotes the
ubiquitination and proteasomal degradation of HdmX, thus the removal of Hdm2 would
be expected to stabilize HdmX. The experiment was repeated and similar results were
observed following knockdown of HdmX and Hdm2 relative to untransfected control
(Con) cells (Western blot not shown).
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Figure 36. HdmX knockdown increases Hdm2 expression. MCF7 cells were
treated with 20 µM MG132 for 4 hours, one day after the final siRNA
transfection, and Hdm2, HdmX, p53, p21, and β-actin were analyzed by Western
blot. p21 expression was induced by loss of HdmX and/or Hdm2, as expected.
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The stability of Hdm2 and p53 over time post cycloheximide in the untransfected control
cells was quantified by measuring the density of the bands normalized to β-actin (Figures
37B and 37C).
Finally, the effect of HdmX or Hdm2 knockdown on normal non-tumor IMR90
cells was investigated. IMR90 cells were triple transfected and total RNA was isolated
24 hours after the third transfection and protein was extracted 48 hours following the
third siRNA transfection. RT-PCR analysis showed a 1.5 fold increase and a 2.5 fold
increase in p21 gene expression following loss of HdmX or loss of Hdm2, respectively
(Figure 38A). These levels of p21 induction are slightly less in IMR90 cells than those
seen in MCF7 cells following triple siRNA transfection (compare Figure 13A to 38A).
Western blot analysis of p21 protein expression correlated with the p21 transcript levels
(Figure 38B). Interestingly, a slight increase in p53 protein was detectable following
loss of HdmX and a greater increase in p53 levels were observed following removal of
Hdm2. This result differs from that seen in MCF7 cells, where a slight increase in p53
protein expression was detected only when both HdmX and Hdm2 were removed. Hdm2
protein levels are low in IMR90 cells and were below the detectable limits of the
antibody/Western blot protocol used. Both siHdmX and sip53 successfully eliminated
HdmX and p53 protein respectively (Figure 38). Beta-actin was used as a loading
control.
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Figure 37.

Loss of Hdm2 stabilizes p53, while loss of HdmX destabilizes

Hdm2. MCF7 cells were treated with 50 µg/mL cycloheximide (CHX) for 0, 1, 2,
and 4 hours following HdmX or Hdm2 knockdown. (A) Western blot of HdmX,
Hdm2, p21 and p53 protein expression. (B) Percentage of p53 protein remaining
over time post CHX treatment relative to time 0. (C) Percentage of Hdm2 protein
remaining over time post CHX treatment relative to time 0. Protein levels were
quantitated by measuring the density of each band relative to β-actin (loading
control). The half-life of p53 was slightly increased by loss of Hdm2. Removal of
HdmX appears to decrease Hdm2 stability relative to untransfected control (Con) or
siCon transfected cells.
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Figure 38. HdmX knockdown in non-tumor IMR90 cells. (A) RT-PCR analysis of
hdmX, hdm2, and p21 gene expression following triple transfection with the indicated
siRNA. (B) Western blot of Hdm2, HdmX, p53, p21, and actin. Hdm2 levels are low in
IMR90 cells, thus were not detectable. p53 is increased following loss of Hdm2, but only
slightly increased by loss of HdmX relative to siCon or untransfected control (con).
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IV. DISCUSSION
A. HdmX knockdown by RNAi
Two RNAi approaches were assessed in this study to knockdown HdmX;
transient transfection of siRNA and stable transduction of shRNA using a lentivirusdelivered shRNA vector. Since lentiviral delivered shRNA has the advantage of stable
long term silencing over transient siRNA transfections, viral shRNA delivery has gained
wide use in creating stable knock-down cell lines. The viral shRNA delivery system is
particularly useful for cells which are difficult to transfect. To investigate the role of
HdmX deregulation of p53 function in tumors with wild-type p53 and overexpressed
HdmX, shRNA vectors were designed containing the same target sequence as the siRNA
used to silence HdmX. Both transient siRNA transfection and shRNA vectors were
effective at decreasing HdmX transcript and protein levels, and at inducing p53 target
genes (Figures 10, 13, 15). Multiple siRNA transfections using Oligofectamine were
especially effective at knocking down HdmX expression with greater than 90% of the
cells taking up the siRNA as determined by siTOX transfection experiments (data not
shown). However, the knockdown of HdmX and Hdm2 by siRNA transfection only
lasted for three and five days, respectively (Figure 14). The knockdown of HdmX in
cells stably expressing shRNA targeting HdmX remained down regulated for up to 30
days, but it too eventually returned to levels of uninfected cells. The loss of knockdown
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over time in stable cell lines has been reported previously and is hypothesized to occur
because high expression levels of shRNAs are cytotoxic to cells (Fish and Kruithof,
2004). Neither the siRNA control nor the shRNA control vectors affected HdmX
expression relative to mock transfected or uninfected cells, respectively. Surprisingly,
the expression of control shRNA vectors (shLamin, shLacZ, or sh scrambled sequence)
triggered activation of the p53 target genes, p21 and gadd45, in several tumor cell lines
(Figure 15 and data not shown). Since all three control shRNA vectors tested induced
non-targeted genes suggests that this is a sequence-independent effect. Transfection of
siRNA control (siCon) which does not target any known genes, did not alter the p53
target genes examined (Figure 13). Previous reports have shown that the viral DNA
integration process and survival of transduced cells requires ATR kinase activity which
leads to a DNA damage response (Daniel et al., 2003). Thus the non-specific induction
of p21 with lentiviral-delivered shRNA vectors could have been the result of the viral
DNA integration process. However, since infection with lentivirus expressing the
Tetracycline repressor gene (Figure 15A) did not induce p21 transcripts, the possibility
that the off-target p21 induction was due to a general anti-viral response by the cells was
excluded. To determine if the non-targeted induction of p21 by the lentivirus-delivered
shRNA control vectors is p53-dependent, two p53-null tumor cell lines were infected
with lentivirus containing shRNA. In the HCT116 cells containing wild-type p53 and in
the HCT116 cells devoid of p53, p21 protein and transcript levels were increased in both
the shHdmX and shLacZ expressing cells relative to uninfected (Figure 16). The
induction of p21 was greater in the HCT116-p53+/+ cells compared to the HCT116-p53/- cells as expected since the lentivirus-delivered shRNA vectors increased p53 protein
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levels (Figure 16A) and p53 transactivation (Figure 18). Likewise, p53-null Saos-2 cells
stably infected with lentivirus containing shHdmX and shLacZ also expressed elevated
levels of p21; implying that the induction of p21 by the shRNA vectors was
predominantly p53-independent (Figure 17).
In an effort to uncover the mechanism by which shRNA vectors were triggering
the non-specific induction of p21, the gene expression of OAS1 and IFIT1, two interferon
response genes, was determined following RNAi (Bridge et al., 2003). While the three
cell lines tested showed variable levels of OAS1 activation after lentiviral shRNA
infection, they all consistently expressed 2-4 fold increases in p21 mRNA (Figure 18).
These results suggest that the level of interferon activation does not correlate with the offtarget p21 induction being triggered by the lentiviral delivered shRNA vectors. Given
that interferon has been reported to activate p21 in MCF7 cells (Gooch et al., 2000), the
cells were treated with interferon-gamma (IFN) and OAS1 and p21 mRNA levels were
measured by real-time PCR. Surprisingly, IFN treatment did not induce p21 gene
expression in either MCF7 cells or HCT116 cells (Figure 21). However, given that
induction of OAS1 and IFIT1 was detected upon IFN treatment in both MCF7 and
HCT116 cells, indicates that both of these cell lines possess an interferon response
mechanism (Figure 20 and 21). Taken together, these findings suggest that an interferon
response to the lentivirus delivered shRNAs does not account for all the non-specific
induction of p53 target genes in the tumor cell lines examined.
Although the non-targeted induction of p53 target genes like p21 and gadd45 did
not result in a level of protein induction sufficient to trigger a significant cell cycle arrest
(data not shown), these results still raise concern regarding the use of lentiviral-delivered
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shRNAs to study gene function in tumor cells. Clearly the presence and/or processing of
the lentiviral-delivered shRNA vectors appeared to cause a non-specific cellular stress
that is altering the expression of untargeted genes. Given these results, transient siRNA
transfection was selected as the method of choice for the GeneChip experiment over the
shRNA vectors due to the induction of off-target genes in cells expressing shRNA
vectors. Others have also raised concerns with constitutive shRNA expression using
lentiviral shRNA vectors employing polIII promoters (Liu et al., 2004; Makinen et al.,
2006). The utilization of a tetracycline inducible lentiviral shRNA system (Szulc et al.,
2006; Wiznerowicz et al., 2006; Wiznerowicz and Trono, 2003) was also assessed as a
way to minimize the non-specific effects on untargeted genes such as p21. However,
there were many issues with this system as well. I am currently investigating other vector
systems to deliver shRNA that are not lentiviral based to determine if this non-specific
gene induction is specific to lentiviral vectors or any shRNA vector. Although the exact
mechanism of the cellular stress caused by the lentiviral-delivered shRNAs that trigger
p53 activation and induction of p53 target genes remains unclear, this study demonstrates
that neither an interferon response nor a sequence specific effect is the cause of these
alterations in gene expression.
B. Alterations in Gene Expression following loss of HdmX
While half of all human tumors possess p53 mutations, inactivation of wild-type
p53 can also occur through a variety of mechanisms that do not involve p53 gene
mutation or deletion. Diverse approaches have been proposed to reactivate wild-type p53
protein in those tumors which do not harbor p53 mutations. Recent studied have
uncovered that the activation of p53 is blocked in human tumors harboring elevated
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levels of HdmX (Danovi et al., 2004; Laurie et al., 2006), suggesting that HdmX:p53
interaction is a relevant and novel target for therapeutic approaches. For these reasons,
an Affymetrix GeneChip experiment was performed to determine how loss of HdmX or
Hdm2 affects global gene expression in MCF7 cells. MCF7 cells were chosen because
they possess wild-type p53 and elevated levels of HdmX and Hdm2 (Ramos et al., 2001).
The overexpression of HdmX and/or Hdm2 is one mechanism to inactivate wild-type p53
and the inactivation of the p53 signaling pathway is essential for tumor formation
(Danovi et al., 2004; Laurie et al., 2006; Toledo and Wahl, 2006). Lists of genes that
were induced by at least two fold or suppressed by at least 50% following knockdown of
HdmX or Hdm2 were created using GeneSpring software (Table 4). The datasets were
initially screened for known p53 target genes since my hypothesis is that loss of HdmX
will activate p53 and induce p53 target genes. As expected, a subset of p53 target genes
was induced, however this set of genes only accounted for 10-15% of the total genes on
the lists. It is difficult to estimate how many genes out of the total number of known p53
target genes this subset represents, since there is not an all inclusive list of p53 target
genes available (Levine et al., 2006; Qian et al., 2002). Interestingly, the subset of p53
target genes that were induced upon HdmX or Hdm2 knockdown predominantly encoded
proteins associated with cell cycle arrest and growth inhibition (Table 5). Included on
this list are a couple of less well known p53 target genes reported to inhibit cell growth,
ACTA2 (smooth muscle actin alpha 2) (Comer et al., 1998) and wig-1 (Hellborg et al.,
2001). In contrast, only one p53 dependent pro-apoptotic gene (i.e. Fas) was increased.
This result was surprising, and implies that the knockdown of HdmX or Hdm2 may not
be a viable antitumor therapeutic approach since it only induced one apoptotic p53 gene.
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A comparison of the genes induced following loss of HdmX to the genes induced
following loss of Hdm2 in the MCF7 cells found 144 genes common to both lists. Thus,
there were similar patterns of p53 target gene activation in the MCF7 cells lacking either
HdmX or Hdm2 indicating that loss of either negative regulator would lead to the same
outcome, predominantly cell cycle arrest. The concurrent knockdown of HdmX and
Hdm2 led to either synergistic or additive activation of several p53 target genes as
determined by RT-PCR (Figure 23). Furthermore, the induction of these target genes are
p53-dependent, as no induction of these p53 target genes where observed after HdmX or
Hdm2 knockdown in several p53-null tumor cell lines (Figures 24B and 25). These
findings in MCF7 breast cancer cells are in contrast to recent mouse model studies
whereby removal of p53 from adult tissues lacking either Mdm2 or MdmX, led to distinct
and synergistic effects between the two proteins depending on the tissue examined
(Boesten et al., 2006; Francoz et al., 2006; Maetens et al., 2006; Marine et al., 2006;
Xiong et al., 2006). The removal of HdmX was anti-proliferative in some tissues, while
loss of Hdm2 caused apoptosis. Additionally, the removal of both caused extensive cell
damage and synergistic expression of several p53 target genes. Other studies to elucidate
the mechanisms by which Mdm2 and MdmX regulate p53 imply that MdmX regulates
p53 transactivation, while Mdm2 controls p53 stability but does not control
transcriptional activity per se (Toledo et al., 2006). Here I observe that in MCF7 tumor
cells, knockdown of HdmX or Hdm2 appear to have similar, but synergistic effects on
p53 activity and gene expression. To examine how loss of HdmX and/or Hdm2 effects
p53 transactivation, a p53 luciferase reporter was tranfected into MCF7 cells lacking
HdmX and/or Hdm2. Interestingly, loss of HdmX resulted in greater p53 transcriptional
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activity than loss of Hdm2, and the combined knockdown was similar to loss of HdmX
alone (Figure 26). These results support the hypothesis that the primary function of
HdmX is to regulate p53 transactivation, while Hdm2 is not as effective at regulating p53
transcriptional activity. Additionally, since Hdm2 can ubiquitinate HdmX and mediate
HdmX degradation (de Graaf et al, 2003; Pan and Chen, 2003; Marine and Jochemsen,
2004), the loss of Hdm2 may lead to more HdmX available to bind p53. Thus, the
balance between HdmX and Hdm2 levels appears to be critical for the regulation of p53,
which is in agreement with the mutual dependency model (Gu et al., 2002).
The elimination of p53 via siRNA in MCF7 cells led to significant decreases in
the expression of p53 target genes associated with both cell cycle arrest and apoptosis
(Table 5). Therefore, the lack of pro-apoptotic genes induced following the loss of
HdmX or Hdm2 is not due to the inability of these genes to be regulated by p53. In fact,
several p53 regulated pro-apoptotic genes were activated when MCF7 cells were treated
with the DNA damaging agent, doxorubicin (Figure 27 and data not shown). It is clear
from the GeneChip experiment that HdmX or Hdm2 knockdown in MCF7 cells results in
p53 transactivation of a subset of target genes that are predominantly involved in cell
cycle arrest and growth inhibition.
How activated p53 selectively turns on one subset of genes or another subset of
genes is still unclear. The two most studied biological outcomes of p53 activation are
cell cycle arrest and apoptosis. The induction of cell cycle arrest occurs as a result of p53
transcriptional activation of the CDKN1A gene that encodes p21, a cyclin-dependent
kinase (CDK) inhibitor (Prives and Hall, 1999). The p21 protein prevents cell cycle
progression and causes a G1 cell cycle arrest by associating with and inhibiting cyclin-
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CDK complexes (el-Diery et al, 1993; Harper et al, 1993). The induction of apoptosis by
p53 is less understood, however it has been suggested that the BCL-2 family is important,
especially the transactivation of NOXA and PUMA (Nakano and Vousden, 2001; Oren,
2003; Shibue et al., 2006; Yu et al., 2001). In this study, CDKN1A was induced by loss
of HdmX and Hdm2, but neither NOXA nor PUMA were altered. The activation of p21
following HdmX knockdown correlates with previous reports (Gu et al, 2002; Linares et
al, 2003; Danovi et al, 2004), however the induction of a subset of other p53 target genes
involved in growth inhibition uncovered in this study is a novel finding. In addition to
GeneSpring, Ingenuity Pathway Analysis (IPA) software was used to identify unique
genes and pathways that may be regulated by HdmX. The lists of genes induced and
suppressed following the loss of HdmX in MCF7 cells were uploaded into the IPA
software. Several different networks or pathway maps were created from the gene lists,
which enabled me to identify unique interactions between genes or the proteins that they
encode which may not be obvious. The pathway map associated with p21 (Figure 39)
contained the greatest number of gene expression alterations, thus emphasizing that the
induction of p21 is a key outcome of HdmX or Hdm2 knockdown in MCF7 cells. It
would be interesting to knockdown p21 in combination with siHdmX or siHdm2 to
evaluate the biological effect and role of p21.
To understand how the loss of HdmX or Hdm2 in MCF7 cells could lead to p53
transactivation and the induction of a specific subset of p53 target genes, p53
phosphorylation was assessed using phospho-specific antibodies. Post-translational
modifications of p53 are induced by various genotoxic stresses leading to p53
stabilization and increasing transactivation (Unger et al, 1999; Lavin and Gueven, 2006).
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Figure 39. Ingenuity Pathway Analysis of genes altered by HdmX knockdown in
MCF7 cells. The network shows cellular localization of the gene products induced (red)
and suppressed (green).
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While a slight increase in p53 protein level was observed when both HdmX and Hdm2
were eliminated concurrently in MCF7 cells, no significant p53 phosphorylation was
detected on serines 6, 15, 20, 46, or 392 (Figure 27). Since the siRNA knockdown of
HdmX or Hdm2 did not trigger p53 phosphorylation or a significant induction of p53
protein suggests that the knockdown of HdmX or Hdm2 did not elicit a genotoxic stress.
These results suggest that the increase in p53 transactivation and induction of p53 target
genes is the result of nongenotoxic activation of p53. The successful activation of p53 in
a nongenotoxic fashion was demonstrated with the small molecule Nutlin, which inhibits
the p53:Mdm2 interaction, thus leading to activation of p53 (Vassilev, 2004). Other
nongenotoxic stresses that have been shown to induce a p53 response include premature
senescence, hypoxia, osmotic shock, and microtubule disruption (Lavin and Gueven,
2006).
C. Biological effects of HdmX knockdown.
After examining the list of p53 target genes induced following the loss of HdmX
or Hdm2, and how the increase in p53 transactivation was not due to p53
phosphorylation, the biological effects of HdmX and Hdm2 knockdown was assessed in
MCF7 cells. As expected, a significant decrease in colony formation was observed upon
the loss of either HdmX or Hdm2 with the greatest decrease occurring when both HdmX
and Hdm2 were removed (Figure 28). Similarly, in a less stringent cell proliferation
assay, knockdown of HdmX or Hdm2 led to a 30% reduction in cell growth, whereas the
concurrent knockdown of HdmX and Hdm2 led to 50% reduction in growth after 48
hours (Figure 29). These results are consistent with the synergistic induction of the antiproliferative genes, p21, BTG2, and ACTA2 observed following loss of both HdmX and
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Hdm2 (Figure 23). MCF7 growth curves also showed that cell proliferation was
inhibited by the elimination of HdmX and/or Hdm2 (Figure 30), particularly when HdmX
and Hdm2 levels were coordinately down regulated by the transient siRNA. Since one
function of Hdm2 is to regulate p53 stability through ubiquitin-mediated proteasome
degradation, knockdown of Hdm2 was expected to increase p53 protein levels in addition
to increase p53 transactivation. However, no dramatic change in p53 protein levels
following Hdm2 knockdown were observed by Western blot analysis (Figures 13, 26 and
27). This is most likely not the result of MCF7 cells being unable to degrade p53, as the
overexpression of Hdm2 in these cells can lead to p53 degradation (S. Berberich,
personal communication). To determine if Hdm2 is capable of E3 ligase activity in
MCF7 cells, p53 ubiquitination could be monitored under the various siRNA conditions.
Since HdmX levels are elevated in MCF7 cells, it may be preventing Hdm2 from binding
p53 efficiently, thus the removal of Hdm2 would have little effect on p53 stability.
Another possible explanation for the lack of p53 stability following loss of Hdm2 is that
other E3 ligases such as Pirh2 and COP1 are preventing an increase in p53 protein levels.
Taken together, these results suggest that the overexpression of HdmX and Hdm2 in
MCF7 cells appears to inactivate p53 primarily through inhibition of transcription.
To assess how the decrease in cell growth and the activation of cell cycle arrest
genes affect cell cycle progression, DNA content was analyzed by flow cytometry. As
expected, the loss of either HdmX or Hdm2 led to a significant increase in G1 cells and a
subsequent decrease in S phase cells in both MCF7 and U2OS cells (Figures 31 and 32).
Since p21 inhibits cyclin-CDK complexes (Xiong et al, 1993) and BTG2 down regulates
the cyclins (Boiko et al, 2006) an arrest in cell cycle progression was anticipated. Thus,
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the gene expression profiles, colony formation, growth curves and cell cycle profiles are
all consistent with the removal of HdmX or Hdm2 leading to a cell cycle arrest that is
dependent on wild-type p53. Interestingly, the gene expression results in this study
correlate with a recent report that showed that during replication senescence of a normal
human cell, p53 preferentially targets genes that induce cell cycle arrest (Jackson and
Pereira-Smith, 2006). Since the loss of HdmX or Hdm2 seemed to preferentially induce
growth arrest genes also, suggests that HdmX removal leads to a similar phenotype as
replication senescence. The hypothesis that HdmX or Hdm2 knockdown leads to cellular
senescence was tested by beta-galactosidase staining; however, no differences in the
numbers of senescent cells were observed between MCF7 cells with or without HdmX or
Hdm2 (data not shown). These experiments were performed following transient siRNA
transfection, thus the long term effect of HdmX or Hdm2 knockdown on cellular
senescence may produce a different result.
Although the removal of overexpressed HdmX or Hdm2 in tumor cells harboring
wild-type p53 appears to be limited to an anti-proliferative effect, the ability to sensitize
cells to chemotherapeutic agents by knockdown of HdmX was examined. Recent studies
have shown that removal of HdmX will sensitize tumors with overexpressed HdmX to
p53 activation by Nutlin (Hu et al., 2006a; Patton et al., 2006), and that cells transfected
with MdmX siRNA showed a more robust p53 response to ionizing radiation (Laurie et
al., 2006). To examine how the removal of HdmX or Hdm2 would affect the sensitivity
of MCF7 cells to various chemotherapy agents, cell viability assays were performed.
Removal of HdmX or Hdm2 in MCF7 cells increased the cytotoxicity of DNA damaging
agents such as doxorubicin and cisplatin, and of the DNA replication inhibitor, AraC
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(Figures 33 and 34). As predicted by the alterations in gene expression, colony
formation, and cell proliferation assays, the knockdown of both HdmX and/or Hdm2 led
to the greatest cytotoxicity. At high doses of the chemotherapy drugs, the enhanced cell
death benefit of HdmX or Hdm2 knockdown was lost. Therefore, removal of HdmX or
Hdm2 sensitizes the cells to lower doses of the chemotherapeutic agents, while still
achieving the same efficacy as the higher doses. Similar results where reported with
other agents, suggesting that tumors with overexpressed HdmX are generally less
sensitive to chemotherapy drugs and that knockdown of HdmX increases their
chemosensitivity (Gilkes et al., 2006). In contrast, the nongenotoxic activation of p53
with Nutlin demonstrated that the presence of p53 protected human tumor cells from
chemotherapy treatments that induce S-phases arrest (Kranz and Dobbelstein, 2006).
Unlike the report from Kranz and Dobblestein, the loss of HdmX or Hdm2 in MCF7 cells
increased the cytotoxicity of both DNA damaging agents and agents which inhibit DNA
replication (Figure 34). These results suggest that HdmX is an important therapeutic
target that may improve current chemotherapy treatments for those human tumors
harboring wild-type p53 and elevated levels of HdmX.
D. p53 and Hdm2 localization and stabilization following loss of HdmX
Since HdmX directly interacts with both Hdm2 and p53, the cellular localization
and stability of Hdm2 and p53 were examined following the loss of HdmX. HdmX is
predominantly a cytoplasmic protein, where as Hdm2 can shuttle between the nucleus
and cytoplasm due to the presence of nuclear localization and export signals (Shvarts et
al., 1996; Roth et al., 1998; Migliorini et al., 2002). One possible function of HdmX may
be to retain Hdm2 in the cytoplasm away from p53 to facilitate p53 activation. If this is
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true, then the loss of HdmX would shift the nuclear and cytoplasmic distribution of
Hdm2. To test this hypothesis, nuclear and cytoplasmic fractionation was performed
from MCF7 cells with and without HdmX knockdown. Western blot analysis revealed
no significant alterations in Hdm2 or p53 cellular localization following the removal of
HdmX (Figure 36). Similarly, the loss of Hdm2 did not appear to alter HdmX or p53
localization. In contrast, others have observed that the knockdown of HdmX led to a
more nuclear Hdm2 pool (K. Huang, personal communication), however these studies
were conducted in p53-null cell lines suggesting that the removal of p53 may alter the
interdependence of Hdm2 and HdmX cellular localization. It would be interesting to
knockdown p53 and HdmX, or p53 and Hdm2 simultaneously using siRNA and monitor
the nuclear and cytoplasmic distribution to determine if p53 plays a role in the
interdependence of Hdm2 and HdmX localization.
The relative abundance of HdmX and Hdm2 appears to be critical to p53 stability
(Gu et al., 2002; Stad et al., 2001). Previous reports show that overexpressed MdmX
protects p53 from Mdm2-mediated degradation by competing with Mdm2 for direct
binding to p53 (Jackson and Berberich, 2000; Mancini et al., 2004). It has also been
shown that overexpressed HdmX protects p53 by enhancing the auto-ubiquitination and
degradation of Hdm2 (Linares et al., 2003; K. Huang, personal communication). To
examine the stability of Hdm2 and p53 following knockdown of HdmX, MCF7 cells
were treated with a proteasome inhibitor, MG132. My results show that the loss of
HdmX increased hdm2 gene expression, but not Hdm2 protein level implying that the
removal of HdmX leads to a decrease in Hdm2 stability. This finding is in contrast to
Linares et al., and K. Huang, however, a previous study has shown that overexpressed
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MdmX stabilized Mdm2 (Sharp et al., 1999). Western blot analysis of Hdm2 showed
that Hdm2 protein levels were increased following the loss of HdmX when proteasomal
degradation was inhibited (Figure 36). This result suggests that although Hdm2
transcription is induced by HdmX knockdown via p53 activation, the Hdm2 protein is
being degraded at an accelerated rate thus, no net change in Hdm2 protein level is
detectable. Additional experiments to assess HdmX, Hdm2, and p53 half-life following
siRNA transfection were performed using cycloheximide to inhibit protein synthesis. As
expected, loss of Hdm2 increased the half life of p53 slightly, whereas elimination of
HdmX had little effect on p53 stability. This is consistent with the idea that HdmX
predominantly regulates p53 transactivation, while Hdm2 controls p53 stability (Figure
37). The removal of HdmX, a binding partner of Hdm2, appears to decrease Hdm2
stability possibly by leaving Hdm2 more accessible to auto-ubiquitination and
proteasomal degradation. This result agrees with Sharp et al. who suggested that HdmX
is necessary for the stabilization of Hdm2. Interestingly, loss of Hdm2 in MCF7 cells
appears to destabilize HdmX also (Figure 37) suggesting that Hdm2 and HdmX
heterodimerization is required for the stability of both proteins. Another possible
explanation is that some other protein may ubiquitinate HdmX in non-stressed cells while
Hdm2 promotes HdmX degradation following damage. It is also hypothesized that
HAUSP may not bind HdmX as effectively without Hdm2, thus it is not deubiquitinated
at the same rate. Previous reports using siRNA to silence HdmX show that knockdown
of HdmX decreases Hdm2 protein stability in one study, while others report an increase
in Hdm2 stability (Gu et al, 2002; Linares et al, 2004). Further experiments will be
necessary to specifically resolve how and under what conditions Hdm2 and HdmX affect
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the stability of each other. It will be necessary to determine if the presence of p53
influences the stability of HdmX or Hdm2 following the knockdown of the other one of
these proteins. Also, the stability of HdmX and Hdm2 upon DNA damage will need to
be assessed when Hdm2 or HdmX is removed. This may determine if other factors are
critical for the regulation of Hdm2 and HdmX stability. Furthermore, immunofluorescence assays could be used to evaluate localization of HdmX and Hdm2 which
may impact stability.
Finally, the effect of HdmX or Hdm2 knockdown on normal non-tumor IMR90
cells was investigated. The loss of HdmX or Hdm2 induced p21 gene and protein
expression as expected, however, to a slightly lower extent than in the MCF7 cells
(compare Figure 13A to 38A). Interestingly, p53 protein expression was increased after
HdmX or Hdm2 knockdown in IMR90 cells. The activation of p53 protein expression
was greater following loss of Hdm2 than after the loss of HdmX (Figure 38B), which
correlates with the role of Hdm2 as a regulator of p53 stability. In contrast, no significant
increase in p53 protein levels was observed via Western blot following the loss of HdmX
or Hdm2 in the MCF7 cells (Figures 13, 26, and 34). The difference in p53 protein levels
between the non-tumor IMR90 cells and the breast carcinoma MCF7 cells may be due to
the overexpression of both HdmX and Hdm2 in MCF7 cells. Results from this study
suggest that both HdmX and Hdm2 must be removed from MCF7 cells to induce even a
slight increase in p53 protein levels. Regardless of the lack of induction of p53 protein
expression, the biological effect of eliminating either HdmX or Hdm2 in MCF7 cells was
sufficient to inhibit cell growth and colony formation. The biological effect of the
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increased expression of p53 protein in IMR90 cells following the knockdown of HdmX
or Hdm2 still needs to be assessed.
Taken together, the results from these studies in MCF7 cells support a model
(Figure 40), whereby the RNAi knockdown of HdmX leads to a nongenotoxic activation
of p53, the induction of p53 target genes predominantly associated with cell cycle arrest
or growth inhibition, and a possible decrease in Hdm2 stability. Additionally, these
results support my hypothesis that loss of HdmX in tumor cells with overexpressed
HdmX and wild-type p53 activates p53, is anti-proliferative, and enhances the
chemosensitivity of the cells to DNA damaging agents.
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Figure 40. Proposed mechanism of p53 activation following loss of HdmX in MCF7
cells. Loss of HdmX leads to a nongenotoxic activation of p53, induction of p53 target
genes predominantly associated with cell cycle arrest, and a possible decrease in Hdm2
stability. Taken together, the loss of HdmX in tumor cells with overexpressed HdmX and
wild-type p53 leads to an anti-proliferative effect, and enhances the cytotoxicity of
chemotherapeutic agents.
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V. CONCLUSION
This dissertation research systematically addresses the effects of loss of HdmX
and Hdm2 on gene expression and cell growth in tumors with wild-type p53 and
overexpressed HdmX and/or Hdm2. RNAi approaches were utilized to silence HdmX,
Hdm2, or p53 either individually or in selected combinations. Using Affymetrix
GeneChips and subsequent RT-PCR validations, a subset of p53 target genes induced
following HdmX or Hdm2 knockdown were uncovered. These target genes encode
proteins predominantly associated with cell cycle arrest and growth inhibition. The
induction of these genes resulted in increased p53 transactivation, and occurred in a p53
dependent manner. The increase in p53 transcriptional activity following the loss of
HdmX or Hdm2 was not due to p53 phosphorylation, implying a nongenotoxic p53
activation. Results from colony formation and cell proliferation assays were consistent
with the induction of genes involved in cell cycle arrest. Flow cytometry analysis of
DNA content was used to confirm that the removal of HdmX or Hdm2 led to a significant
G1 cell cycle arrest. Furthermore, HdmX or Hdm2 knockdown in MCF7 cells sensitized
the cells to several chemotherapeutic agents. Taken together, these results suggest that
removal of HdmX may be an important therapeutic strategy that would enhance the
efficacy of chemotherapy drugs currently used to treat human tumors possessing wildtype p53 and overexpressed HdmX.
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